

RICHARD SEGAL
Professor and Associate Chair
Director of Graduate Studies

OFFICE: University of Florida
1889 Museum Road
Suite 6300
Gainesville, FL 32611

PHONE: (352) 273-6265
FAX (352) 273-6270
E-Mail segal@cop.ufl.edu

EDUCATION

Virginia Commonwealth University-Medical College of Virginia
Department of Pharmacy and Pharmaceutics, Ph.D., 1983
Major Area: Pharmaceutical Outcomes Research
Supervisor: Charles D. Hepler

University of Iowa, M.Sc., 1981
Major Area: Hospital and Clinical Pharmacy
Supervisor: Charles D. Hepler

Mayo School of Health Sciences
ASHP Accredited Residency in Hospital Pharmacy completed at Saint Mary's Hospital/Mayo Clinic,
Rochester MN, 1976-77

University of Connecticut, School of Pharmacy, B.S. in Pharmacy, 1976

SPECIAL TRAINING

Academic Administration Program, University of Florida, 1994
School on Alcoholism and Other Drug Dependencies, University of Utah, 1993
Certificate of Training in Geriatrics and Gerontology, University of Florida Geriatric Education Center, 1989
PMA Visiting Professor, Ortho Pharmaceutical Corporation, 1984

PROFESSIONAL LICENSURE

Registered Pharmacist in Iowa - #S15203

RESEARCH INTERESTS

Designing Systems to Reduce Preventable Drug-Related Morbidity, Adverse Drug Events, and Medication Errors
Pharmaceutical Care/Medication Therapy Management Program

PROFESSIONAL POSITIONS

University of Florida

Director of Graduate Studies, 2014 – present
Associate Chair, 2020 – present
Associate Dean for Faculty Affairs, 2014 – 2020
Professor, Department of Pharmaceutical Outcomes & Policy and Department of Pharmacotherapy and Translational Research, 1988 to present (promoted from Associate Professor in 1994)
Faculty, Center for Drug Evaluation and Safety, 2019 to present
Director of Research, Center for Quality Medication Management (CQM), University of Florida
Special Government Employee (SGE), FDA, Drug Safety and Risk Management Advisory Committee, Member, 2015 – present
University of Ibadan (Nigeria): Courtesy Professor, Faculty of Pharmacy, Clinical Pharmacy and Pharmacy Administration, 2015 to present
Member, UF Shands Cancer Center, 2011 to present
Dr. Robert and Barbara Crisafi Endowed Chair in Pharmaceutical Outcomes and Policy and Medication Safety, 2011-16.
Chair, Department of Pharmaceutical Outcomes & Policy, 1995 to 2014
University of Florida Research Foundation Professor
Professor, Health Services Research, Management, and Policy, College of Public Health, 2000 to 2017
Faculty, Florida Center for Medicaid and the Uninsured, 2002 to 2013
Director, Center for Research in Pharmaceutical Care, 2000 to 2010

Ohio State University

Associate Professor (with tenure), Division of Pharmaceutical Administration, 1983-1988, promoted from Assistant Professor in 1988
Director, Graduate Program in Hospital Pharmacy, 1986 -88
Director, Graduate Program in Pharmaceutical Administration, 1985-86

AWARDS AND HONORS

2021, Teacher of the Year, College of Pharmacy
2021, Paul Doering Excellence in Teaching Professor award
2020 APhA-APPM Presentation Merit Award *Finalist*, American Pharmacists Association. Menendez L, Marks Y, Wallace J, Segal R. Partnering community health workers with pharmacists to improve adherence and blood pressure control in a culturally diverse population.

Silver Award for Zeigler M, Wheat M, Kim J, Wallace J, Wilson S, **Segal R**. Resolution of Adherence Barriers and Blood Pressure Reduction after a Community Health Worker Training Program in Collaboration with Pharmacists. Presented at AMCP, Orlando, FL, Oct 24, 2018.

Outstanding Team Teaching Award for 1PD course called "Principles of Patient Centered Care," Course Coordinator, May 2017

Silver Award for "Factors Associated with Time to Complete a Comprehensive Medication Review for Medicare Part D MTM-Eligible Beneficiaries." Presented at AMCP, San Francisco, CA, April 2016.

Dr. Robert and Barbara Crisafi Endowed Chair in Pharmaceutical Outcomes and Policy, 2011-16

Gold Award for "Examining Alternate Standardized Scripts to Improve Comprehensive Medication Review Participation Rate." Presented at AMCP, Orlando FL, October 27, 2015

Honorable Mention for Best Research Presentation in the Resident/Fellow Category. AMCP 25th Annual Meeting & Expo, April 3-5, 2013, San Diego California

Winner of the APHA-APRS 'Postgraduate Best Paper Award' in the Clinical Sciences section. Presented at the 2004 APHA Annual Meeting in Seattle, 2004

"Best of Blue" National Award selected by Blue Cross Blue Shield for the research project entitled "Impact of an Antidepressant Management Program on Measures of Medication Compliance." 2001

NACDS Student Research Award, Faculty Mentor, 2001

University of Florida Research Foundation Professor, 1999-2001

American Pharmaceutical Association Best Published Paper Award for Economic, Social, and Administrative Sciences, 1999

Phi Lambda Sigma National Leadership Society, 1998

American Society of Health-Systems Pharmacy Award for Practice Research, 1997

Searle Fellowship in Pharmacy - Second Place Award to Faculty Mentor, 1996

Searle Fellowship in Pharmacy - First Place Award to Faculty Mentor, 1995

Glaxo Pharmacoconomics Award. 1994

Smith Kline & French Research Award for Hospital Pharmacy Practice in 1989

Upjohn Award for Research in Clinical Pharmacy in 1988

Smith Kline & French Tagamet Investigator's Award (Hon. Mention), 1988

Central Ohio Society of Hospital Pharmacists Research Award, 1987

Central Ohio Society of Hospital Pharmacists Research Award, 1985

A.D. Williams Fellow at Medical College of Virginia, 1982

Rho Chi National Honor Society

Sigma Xi

Mortar and Pestle Society

Certificate of Merit, Connecticut Pharmaceutical Association

Edwards Honor Scholarship

PROFESSIONAL ACTIVITIES

University of Florida Activities

Planning Committee, NCI-funded "6th Biennial Science of Global Prostate Cancer Disparities in Black men Conference, November 11 -14, 2021.

University of Florida Fairness and Equity in Assessment Task Force, 2021

Scientific Abstract Reviewer for Annual Meeting, AACP, 2021

University of Florida Sick Pool Committee, Academic Member, 2017- 2021

NIH/NCI Special Emphasis Panel, ZCA1 PCRB-G, Member, November 2016, June 2017, October 2017, March 2018, June 2018

Academic Freedom, Tenure, Professional Relations and Standards Committee, Member 2004 –15, Chair 2012-15, Member 2018- 2021

PharmD Admissions Committee, 2001 – present

Tenure & Promotions Committee, 1992 -94, 1996-98, 2016 to present

Faculty Governance Council, Chair (2009-10 and 2011-2013), Member (2007-09, 2013-14, 2015-2020)

Graduate Studies Committee, 2015 to present

Student ASHP/FSHP Chapter, Co-Faculty Advisor, 1990 to present

Student SNPhA Chapter, Advisor, 2019 - present

Editorial Advisory Board, "Pharmacy Practice Management: Forms, Checklists & Guidelines "

PQA Stakeholder Advisory Panel C (SAP C), 2017-18

Faculty Practice Association, Board of Directors (Treasurer and Secretary), 1999 to present

Scientific Review Committee (Chair), The Science of Global Prostate Cancer Disparities in Black Men, 2010, 2012, 2014, 2016, 2018

American Association of Colleges of Pharmacy (AACP) Faculty Affairs Committee, 2011-12, 2015-17

CTSA, Public-Private Partnerships-Agreement Workgroup, 2009-present

Committee on Impaired Professionals, Chair (1990 – 97, 2014-present), member (2010-13)

Welfare Council, 2012–15

Faculty Senate, 2004 – 2010, 2011-14

Co-Chair, Search committee for chair of medicinal chemistry, 2014

Scientific Advisory Group, Center for Medicaid & the Uninsured, 2006 –14

College of Pharmacy Continuing Education Committee, (Chair), 1999 –14

Chair, Task Force for Curriculum Revision of PharmD Program, 2012

Presidential Task Force on Sustainability, 2004 –06

University Master Plan Steering Committee, 2004 -08

Health Management and Policy Curriculum Development Committee, Public Health Program, 2003-2006

Search Committee for Professors in Health Services Administration, 2000

University-wide Faculty Proposal Review Committee, 1999 -00

Named Presidential Fellowship Selection Committee, University of Florida, 1997-99

College of Health Professions Research Fair, Judge, 1999

Minority Mentor, University of Florida, 1990 -92, 1995-98

Finance and Accounting Advisory Committee, University of Florida, 1992 -94

Placement Committee, University of Florida, 1990 -93

Executive Council, College of Pharmacy, 1995 –13

NCPA Faculty Liaison, 2001 - 08

Search Committee for Eminent Scholar Chair, (Co-chair), 1999-00

Curriculum Committee, 1998 -99

Law & Management Conference Committee, 1989-93, 1996-01 (member or Chair)

Leadership Council, College of Pharmacy, 1995-97

Search Committee for Pharmacy Practice Department Chair. 1997

Graduate Studies Coordinator, 1990-94

Director, Pharm.D./MBA Program, 1989-95

Search Committee for Associate Dean for Research and Graduate Studies, (Chair), 1994

AHEC Faculty Search Committee, Dept. of Pharmacy Practice, 1994.

Coordinating Committee for College of Pharmacy Self-Study (Chair), 1992-93

Graduate Studies Committee, 1990 -94

Financial Aid and Student Awards Committee, 1989 -95

NARD Faculty Liaison for the University of Florida, 1988 -01
 Pharm.D./Ph.D. Promotion Committee, 1992-3
 Task Force on Problem Solving, College of Pharmacy, 1991
 Task Force on Problem-Solving Professionals, (Co-Chair) 1990
 External PharmD Curriculum Committee, 1988-89
 PHCA Faculty Search Committee, (Chair) 1989-90
 Pharmacy Practice Faculty Search Committee, 1990-91

The Ohio State University Activities

Faculty Adviser, Pharmacy Council, 1984-88
 Faculty Co-Adviser, Drug Abuse Educational Committee, 1987-88
 Graduate and Research Committee, 1985-88
 Academic Challenge Undergraduate Research Committee, 1986-88
 Student Affairs Alcohol and Drug Educational Advisory Committee, 1987-88
 Provost's Special Committee for Undergraduate Curriculum Review, 1987-88
 M.S. in Hospital Pharmacy Committee, 1983-88 (Chairman)
 NARD Faculty Liaison for The Ohio State University, 1987
 Self-Study Committee, 1983-85
 Admissions Committee, 1984-85
 Awards, Financial Aids and Honors Committee, 1983-84
 Task Force for Instructional Guidebook, Office of the Vice Provost for Student Affairs, 1985
 AACP Committee on Orienting New faculty, 2009-10
 AACP, Faculty Delegate, 1990 -02, 1999-00, 2001-2002, 2008-09, 2009-10 (Alternate)
 AACP, Curriculum SIG, 2006-07
 Reviewer, Nova Scotia Health Research Foundation, 2002
 Reviewer, Contributed Papers for ASHP Midyear Clinical Meeting, 1997-2002.
 AACP, SAS External Constituencies Committee, 2000-01
 APhA Book Reviewer, 2001.
 AACP Council of Faculties, Graduate programs Standards Committee (member) 1999-00
 AACP Council of Faculties, Faculty Affairs Committee (member) 1997-98
 Co-Author, *ASHP Therapeutic Position Statement on the recognition and treatment of Helicobacter pylori disease.*
 Editorial Board and Column Editor, Pharmacy Practice Management Quarterly, 1995 to 2001
 Editorial Board, Topics in Hospital Pharmacy Management, 1989 -94
 Educational Council, Florida Society of Hospital Pharmacists, 1993-94
 SIMKIN, Inc., Professional Advisory Board, 1992 - 2000
 Du Pont Pharma MBA Educational Support Program Advisory Committee, 1993
 American Public Health Association Medical Care Section, Reviewer of contributed papers, 1993
 GAPS Proposal Review Panel, Priority III, American Association of Colleges of Pharmacy, 1992
 NIH Study Section Member, Clinical Pharmacy and Pharmacology, 1991
 Editorial Advisory Board, "*The Hospital Pharmacy Management Forms, Checklists & Guidelines Manual*," Aspen Publishers
 Trustee, Pharmacist Rehabilitation Organization, Inc., 1987-88
 Consultant to Veterans Administration Outpatient Clinic, Columbus, Ohio, 1986-88
 Council of Legal & Public Affairs, Ohio Society of Hospital Pharmacists, 1987-88
 Professional Affairs Council, Ohio Society of Hospital Pharmacists, 1985-87
 Professional Affairs Committee, Central Ohio Society of Hospital Pharmacists, 1984-88

Legislative Affairs Committee, Central Ohio Society of Hospital Pharmacists, 1983-84
 Reviewer, Research Award Program, Ohio Society of Hospital Pharmacists, 1987
 Co-Editor, Therapeutic Update in the Iowa Pharmacist, 1979
 President, Student American Pharmaceutical Association, University of Connecticut, 1976

PROFESSIONAL SOCIETIES

American Society of Health-System Pharmacists
 American Pharmacists Association
 American Managed Care Pharmacy
 International Society for Pharmacoeconomics and Outcomes Research
 American Association of Colleges of Pharmacy
 Florida Society of Health-Systems Pharmacists
 Kappa Psi Pharmaceutical Fraternity

TEACHING EXPERIENCE

University of Florida

PHA 5103 – Principles of Patient Centered Care (course co-coordinator)
 PHA 5244 – Principles of Evidence Based Pharmacy (course co-coordinator)
 PHA 6265 – Introduction to Pharmaceutical Outcomes & Policy Research (course coordinator)
 PHA 5742 – Professional Communications (course coordinator)
 PHA 5267 – Critical Appraisal in Pharmacoeconomics
 PHA 6291 – Medication Use Systems (course co-coordinator)
 PHA 5239 – Legal & Organizational Environments in Medicines Use
 PHA 5727 – Intro to Pharmacy (course coordinator)
 PHA 5255 - Medication Use Process (course coordinator)
 PHA 5211 - Pharmaceutical Outcomes (course coordinator)
 PHA 5933 – Pharmacy Management (course coordinator)

The Ohio State University

PHARM 521 - Introduction to Pharmacy Operations
 PHARM 523 - Pharmaceutical Information Systems
 PHARM 695 - Pharmacy Seminar - Professional Relationships
 PHARM 816 - Principles of Hospital Pharmacy I
 PHARM 817 - Principles of Hospital Pharmacy II
 PHARM 820 - Drugs, Society and Human Behavior
 PHARM 821 - Research Methodology in Pharmacy Practice
 PHARM 824 - Evaluation of Pharmaceutical Programs
 Graduate Pharmacy Seminar - Research Proposals and Reports

PRESENTATIONS

1. Romonia R Reams, Folake T Odedina, John D Carpten, Knife Redda, Mariana C Stern, Janice Krieger, Jose Aparicio, Brooke Hensel, Nissa Askins, Andre Abreu, Angela Adams, Edward Agyare, Jamel Ali, John M. Allen, Richard Alo, Lourdes Baezconde-Garbanati, Jason Brant, Perry Brown, Sarah Buxbaum, Pinchas Cohen, Wendy Cozen, Miriam O. Ezenwa, Sara Moscovita Falzarano, Roger Fillingim, Hernan Flores-Rozas, Kristianna M Fredenburg, Thomas J. George, Bo Han, Young Huang, Chanita Hughes Halbert, Gebre-Egziabher Kiro, Nazarius S Lamango, Ji-Hyun Lee, Duane Mitchel, Duane A. Mitchell, Bereket Mochona, Jorge J Nieva, Ite A Offringa, Paul Okunieff, Alexander S. Parker, Suhn K Rhie, Joyce Richey, Sherise C Rogers, Bodour Salhia, Thomas D Schmittgen, Richard Segal, Veronica Wendy Setiawan, Ukamaka Smith, Li-Ming Su, Sandra Suther, Jose G. Trevino, Enrique Velazquez Villarreal, Fern J. Webb, Yao Yingwei, Anna H Wu, and Diana J Wilkie. Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center: Structure and Initial Outcomes. *Cancer Epidemiology, Biomarkers & Prevention*.(under submission).
2. Segal R. Therapeutic Outcomes Monitoring (TOM) and medication Therapy Management Interventions. Workshop (invited). DUPHAT, Dubai UAE, January 10, 2024.
3. Segal R. Integrating community health workers into medication therapy management to improve health in a culturally diverse population. Keynote presentation (invited). DUPHAT, Dubai UAE, January 11 2024.
4. Segal R. Chairperson for geriatric pharmacoepidemiology session, including invited presentation on pharmacoepidemiology case control series design issues. (invited). DUPHAT, Dubai UAE, January 11 2024.
5. DeVaughan Circles, A., Nelson, T., Yao, Y., Legaspi, A. Scarton, L. Donahoo, W., Segal, R., Goins R. T., Manson, S., Wilkie, D.J. Lipid-Lowering Medication Adherence in American Indians with Type 2 Diabetes: A Multi-Year Picture. ASHP Midyear, December 2023.
6. Nelson T, Yai Y, DeVaughan, Circles A, Donahoo WT, Wilke DJ, Segal R, Scarton L. Gender differences in glycemic control and adherence to metformin in American Indian adults with type 2 diabetes. APHA 2022.
7. Alalwan AA, Friedman J, Park H, Segal R, Brumback B, Hartzema A. Effectiveness and safety of warfarin use after bariatric surgery in patients with atrial fibrillation and venous thromboembolism: a real-world analysis. ICPE 2022, August 2022 (submitted).
8. Lewis MO, Zhou L, Gellad WF, Hincapie-Castillo JM, Wilkie DJ, Segal R, Wilson D, Lo-Ciganic WH. Geographic Variation of High-Risk Prescription Opioid Use Measures Among Disabled Medicare Beneficiaries, 2011-2018, ISPOR 2022, 15 - 18 May 2022.
9. Alipour-Haris G, Rowe CA, Roane TE, Mobley L, Segal R. Training community health workers to partner with pharmacists to improve medication adherence and blood pressure control in a culturally diverse population during COVID-19 pandemic. Presented at American Pharmacists Association, San Antonio, March 2022.

10. Legaspi A, Wheat L, Roane TE, Connelly A, Zeigler M, Wallace J, Kim JH, Alipour-Haris G, Segal R. Effectiveness of a pharmacist-community health worker team in addressing medication adherence Barriers. UCF Global Health Conference, Orlando FL., January 15, 2022.
11. Segal R. Invited Speaker on pharmaceutical care (lecture followed by workshop), Project Pink-Blue, Upgrade Oncology Program to strengthen the capacity of the Nigerian oncology workforce in partnership with Fulbright Specialist Program, November 2021.
12. Segal R. Moderator, the NCI Biennial Science of Global Prostate Cancer Disparities in Black Men Virtual Conference, November 11, 2021.
13. Menendez L, Marks Y, Wallace J, Segal R. Partnering community health workers with pharmacists to improve adherence and blood pressure control in a culturally diverse population. American Pharmacists Association Annual Meeting & Exposition, National Harbor, MD, March 20-23, 2020. <https://aphaabstracts.secure-platform.com/a/gallery/rounds/1332/details/30038>
14. Segal R. Role of the pharmacist and medication therapy management. Invited presentation at Chronic Disease Summit. Health Planning Council of SWFL. February 18, 2020.
15. Menendez L, Marks Y, Segal R. Partnering community health workers with pharmacists to improve adherence and blood pressure control in a culturally diverse population. University of Florida College of Pharmacy Research Showcase. February 10, 2020.
16. Menendez L, Marks Y, Segal R. Partnering community health workers with pharmacists to improve adherence and blood pressure control in a culturally diverse population. Diversity Day 2020, Public Health and Health Professions, University of Florida, January 30, 2020.
17. Segal R. Incorporating Community Health Workers into the Medication Use System in a Culturally Diverse Population. Keynote presentation at the Florida CHW Certification program, Tallahassee, FL, October 14, 2019.
18. Alalwan A, Segal R, Hartzema A. Comparative safety of sleeve gastrectomy vs. Roux-en-Y: A retrospective longitudinal analysis of a real-world population. Presented at ISPOR Europe, Copenhagen, Denmark, November 2019.
19. Costales B, van Boemmel-Wegmann, Segal R. A Descriptive Analysis of Florida Medical Marijuana Registry Patients from 2016-2017. International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Philadelphia Convention Center, Philadelphia, PA, August 24-28, 2019. *Pharmacoepidemiology & Drug Safety*. Aug 2019;28(S2):264. doi: 10.1002/pds.4864.
20. A Comparison of Immune Checkpoint Inhibitors Approved by the U.S. Food and Drug Administration, Health Canada and the European Medicines Agency (2011-2017). Presented at ISPOR, May 20, 2019, New Orleans.
21. **Segal R**, Wallace J, Wilson S. Effect of incorporating community health workers into the medication use process for hypertensive patients in a culturally diverse population. Primary Care Innovations, University of Florida, March 8, 2019.

22. **Segal R.** Exploring barriers to medication adherence and strategies for improving adherence to asthma. Invited talk to the Florida Asthma Coalition. Ft. Myers, FL, February 22, 2019.
23. Costales B, Boemmel-Wegmann S, **Segal R.** Florida's Medical Marijuana Program: A Descriptive Analysis of Patient Treatment Plans Submitted to the University of Florida College of Pharmacy. Research Showcase, University of Florida, February 11, 2019.
24. Wheat L, Zeigler M, Kim J, Wallace J, Wilson S, **Segal R.** Blood Pressure Reduction Following Resolution of Adherence Barriers after a Community Health Worker Training Program in Collaboration with Pharmacists. Presented at FSHP, November 16, 2018.
25. **Segal R.** Improving Patient Outcomes Using Medication Therapy Management: Hypertension Case Study. Medication Therapy Management International Symposium. University of Ilorin, Ilorin, Nigeria. November 8, 2018.
26. **Segal R.** Keynote: The ABC's of Medication Therapy Management: What, Why, and How? Medication Therapy Management International Symposium. University of Ilorin, Ilorin, Nigeria. November 7, 2018.
27. Wallace J, Wilson S, Kim J, Zeigler M, **Segal R.** Effect of incorporating community health workers into the medication use process for hypertensive patients in a culturally diverse population. ASHP Midyear Clinical Meeting, Anaheim CA, December 2, 2018.
28. Wilson S, Wallace J, Kim J, Zeigler M, Wheat L, Williams T, **Segal R.** Effect of incorporating community health workers into the medication use process for hypertensive patients in a culturally diverse population. Diversity Graduate Research Symposium, Gainesville FL, October 31, 2018.
29. Zeigler M, Wheat L, Kim J, Wallace J, Wilson S, **Segal R.** Resolution of Adherence Barriers and Blood Pressure Reduction after a Community Health Worker Training Program in Collaboration with Pharmacists. To be presented at AMCP, Orlando, FL, Oct 24, 2018. Winner of Silver Medal.
30. Dawwas G, Dietrich E, Winchester D, Winterstein A, **Segal R,** Park H. Comparative effectiveness of prasugrel versus ticagrelor for the prevention of cardiovascular diseases in patients with acute coronary syndrome. Presented at ISPE, Prague, August 26, 2018.
31. Olasupo, O, Brown J **Segal R.** Missed opportunities for influenza and pneumococcal vaccinations in the elderly in the US - a cross-sectional analysis. Presented at ISPOR 23rd Annual International Meeting. Baltimore MD, May 19-23, 2018.
32. **Segal R,** Miller S, James L. Real-time Data-driven Facilitation with Microsoft Forms. Interface: Student Voices Transform Teaching. April 19, 2018.
33. Wallace J, **Segal R,** Zeigler M. Improving Medication Use in a Rural, Culturally Diverse Population through Encounters Involving Community Health Workers in Partnership with Pharmacists. Presented at the UF Florida Society of the Social Sciences (F3S), April 2018.
34. Wheat L, Zeigler M, **Segal R.** Identifying Intervention Opportunities for Medication Adherence Barriers through Pharmacist Collaboration with Community Health Workers. Presented at the AMCP Annual Meeting, Boston MA, April 2018.

35. Wallace J, **Segal R**, Zeigler M. Improving Medication Use in a Rural, Culturally Diverse Population through Encounters Involving Community Health Workers in Partnership with Pharmacists. Presented at the University of Florida College of Pharmacy Research Showcase, February 2018.
36. Wallace J, **Segal R**, Vargas A, Zeigler M, Mobley L. Identifying Medication Use Problems and Improving Minority Health through Community Health Workers. People's Scientific Conference to Promote Minority Health through Community-Based Participatory Research. September 22, 2017, Gainesville, FL.
37. Jiang X, Park H, Xiao H, and **Segal R**. Trends in readmission rate and hospital charge for patients with chronic obstructive pulmonary disease (COPD) in Florida from 2009 to 2014. Presented at ISPOR 22nd Annual International, Boston MA, May 20-24, 2017.
38. Murimi IB, Ghambaran A, Decker R, Liu X, **Segal R**, Loyo-Berrios NI, Marinac-Dabic D, and Hartzema A. Association between recombinant human bone morphogenetic proteins and post-operative opioid use in lumbar fusion procedure patients: a propensity-score matched analysis. Presented at ISPOR 22nd Annual International, Boston MA May 20-24, 2017.
39. Endiakov A, Zeigler M, Hall A, Miguel A, Mostellar D, **Segal R**. Formulary change notification: A two-tiered approach. Presented at the AMCP Meeting, Denver Co, April 2017.
40. Connelly A, Patel AV, Hardin H, Hall A, Salo J, Golub-Neff K, **Segal R**. Analyzing the success rates of pharmacist interventions in resolving medication therapy problems at University of Florida's Medication Management Center. Presented at the AMCP Meeting, Denver Co, April 2017.
41. **Segal R**. Discovering new approaches for helping community pharmacists provide pharmaceutical care. Keynote presentation at FAPA, Bangkok, Thailand, November 2016.
42. **Segal R**. The technology behind flipping a classroom. Presented at Ubon Ratchathani University, Thailand, November 2016.
43. **Segal R**. Pushing the boundaries of pharmaceutical care. Presented at Ubon Ratchathani University, Thailand, November 2016.
44. **Segal R**. Discovering new approaches for helping community pharmacists provide pharmaceutical care. Presented at Chiang Mai University, Thailand, November 2016.
45. **Segal R**. Team-based learning in pharmacy education. Presented at Chiang Mai University, Thailand, November 2016.
46. Nazarov V, Wilkinson R, Neff K, Miguel A, **Segal R**, Mansoor H, Hall A. Factors associated with time to complete a comprehensive medication review for Medicare Part D MTM eligible patients. Presented at the AMCP Meeting, San Francisco, CA, April 2016.
47. Liu X(g), Carney P(&), Bussing R(&), **Segal R**, Cottler L(&), **Winterstein AG(&)**. 2016. Safety of Stimulants in Children with Epilepsy: a retrospective Cohort Study. *Pharmacoepi Drug Saf.* 25(Suppl. 3):34: 25.

48. **Segal R.** Evaluating Cancer Advocacy Programs in Africa. 3rd Cancer Advocacy for African Countries. November 2015, Marrakech, Morocco.
49. Liu W, Antonelli PJ, Dahm P, Gerhard T, Delaney JA, Segal R, Stephen C, Winterstein AG. Comparative Ototoxicity of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction. Presented at Triological Society 2015 Combined Sections Meeting, Coronado Island, CA, January 22-24, 2015.
50. Mansoor H, **Segal R**, Hartzema A. Reproductive years and the risk of cardiovascular events in women: Insights from the National Health and Nutrition Examination Survey (NHANES). *Circulation*. 2015;132:A13697. American Heart Association Annual Scientific Sessions. November 2015. Orlando, FL.
51. Mansoor H, Elgendy IY, **Segal R**, Hartzema A. Reproductive years and the risk of cardiovascular events in women” Insights from the National Health and Nutrition Examination Survey (NHANES). Presented at the American Health Association Meeting, Orlando, FL, November 7-11, 2015.
52. Mansoor H, **Segal R**, Hall A. "Building a predictive risk score for medication non-adherence in hypertensive patients. Presented at AMCP, Orlando, FL, October 27, 2015.
53. Miguel A, Hall A, Liu W, **Segal R**, Koskinas D, Ballew A. Examining Alternate Standardized Scripts to Improve Comprehensive Medication Review Participation Rate. Presented at AMCP, Orlando, FL, October 27, 2015.
54. Choi YY, Eworke E, **Segal R**. What Explains the Different Rates of Human Papillomavirus Vaccination Among Adolescent Males and Females in the United States? Presented at ICPE, 31st *International Conference on Pharmacoepidemiology & Therapeutic Risk Management*, Boston MA, August 22-26, 2015.
55. Knox CA, Hampp C, Brumback B, Xu X, **Segal R**, Winterstein AG. Risk of Preterm Delivery among Live Births Exposed to Anti-diabetic Agents during the First Trimester of Pregnancy. Presented at 31st Conference of Pharmacoepidemiology & Therapeutic Risk Management, August 22-26, 2015, Boston, United States. *Pharmacoepi Drug Saf* 2015;24:249.
56. Knox CA, Hampp C, Brumback B, Xu X, **Segal R**, Winterstein AG. Risk of Cesarean Section Delivery among Live Births Exposed to Anti-diabetic Agents during the First Trimester of Pregnancy. Presented at 31st Conference of Pharmacoepidemiology & Therapeutic Risk Management, August 22-26, 2015, Boston, United States. *Pharmacoepi Drug Saf* 2015;24:250.
57. Knox CA, Hampp C, Brumback B, Xu X, **Segal R**, Winterstein AG. Risk of Preeclampsia among Live Births Exposed to Anti-diabetic Agents during the First Trimester of Pregnancy. Presented at 31st Conference of Pharmacoepidemiology & Therapeutic Risk Management, August 22-26, 2015, Boston, United States. *Pharmacoepi Drug Saf* 2015;24:249-250.
58. **Segal R.** Discussion between Providers and Patients about Prostate Specific Antigen Testing In USA. Presented at ISPOR 20th Annual International Meeting, May 2015.

59. Nazarov V, Wilkinson R, Miguel A, **Segal R**, Mansoor F, Hall A. Factors associated with time to complete a comprehensive medication review for Medicare Part D MTM eligible patients. Presented at AMCP, San Diego, CA, April 2015.
60. **Segal R**. Comparative ototoxicity of phosphodiesterase type 5 inhibitors to treatment of erectile dysfunction. The Triological Society Combined sections meeting, Coronado CA, January 22, 2015.
61. Liu W, Antonelli PJ, Dahm P, Gerhard T, Delaney JAC, **Segal R**, Crystal S, Winterstein AG. Risk of sudden sensorineural hearing loss in adults using phosphodiesterase type 5 inhibitors. 30th Conference of Pharmacoepidemiology & Therapeutic Risk Management, October 24-27, 2014, Taipei, Taiwan. *Pharmacoepi Drug Saf* 2014;23(S1):492-493.
62. Knox CA, Palmsten K, Setoguchi S, **Segal R**, Winterstein AG. Predicting linkage within a validated algorithm that identifies mother-infant pairs within the Medicaid Analytic Extract (MAX) database. 30th Conference of Pharmacoepidemiology & Therapeutic Risk Management, October 24-27, 2014, Taipei, Taiwan. *Pharmacoepi Drug Saf* 2014;23(S1):350.
63. Knox CA, **Segal R**, Winterstein AG. Epidemiology of pre-existing diabetes in pregnancy from 2000-2006 among Medicaid patients in 29 US states. 30th Conference of Pharmacoepidemiology & Therapeutic Risk Management, October 24-27, 2014, Taipei, Taiwan. *Pharmacoepi Drug Saf* 2014;23(S1):312.
64. **Segal R**. The effect of tailored interventions driven by predictive analytic modeling on improving medication adherence for Medicare Advantage prescription drug plan members. AMCP's 26th Annual Meeting & Expo, April 2014.
65. **Segal R**. Evaluation of patient perceptions of their health condition and beliefs about medications before and after pharmacist-provided Medication Therapy Management services in Nontuberculous Mycobacterial Lung Disease, Tampa FL, AMCP's 26th Annual Meeting & Expo, April 2014.
66. Ali AK, Winterstein A, Hendeles L, Lu X, **Segal R**, Hartzema A. Comparison of rates of prescribing oral corticosteroids for asthma exacerbations between step-down therapy approaches among initiators of inhaled corticosteroids and long-acting beta-agonist combination therapy. *Journal of Allergy and Clinical Immunology*. February 2014; 133(2S):AB177 [Abstract No. 611].
67. **Segal R**. Evaluating Community-based Cancer Advocacy Programs, African Organization for Cancer Research, Durban SA, November 2013.
68. Ali AK, Hartzema A, Hendeles L, Lu X, Winterstein A, **Segal R**. Long-acting beta-agonists and asthma exacerbations requiring short courses of oral corticosteroids: a multi-category exposure marginal structural models analysis. *Value in health*; 16(2013) A1-A298.

69. Segal R. Building and Assessing Interventions Focused on Cancer Advocacy, African Organization for Cancer Research, Durban SA, November 2013.
70. Segal R. The Art and Science of Scientific Dissemination, Covenant University, Ota Nigeria, November 16, 2013.
71. Segal R. Issues in Academic and Research Administration, Covenant University, Ota Nigeria, November 16, 2013.
72. Segal R. Improving Patient Outcomes Using Medication Therapy Management: Hypertension Case Study, Covenant University, Ota Nigeria, July 11, 2013.
73. Segal R. Evaluating Medication Therapy Management Programs, Covenant University, Ota Nigeria, July 11, 2013.
74. Segal R. Multidisciplinary Approach to Medication Therapy Management, University of Ibadan, Ibadan Nigeria, July 9, 2013.
75. Segal R. Developing a Research Protocol for Evaluating Medication Therapy Management, University of Ibadan, Ibadan Nigeria, July 9, 2013.
76. **Segal R.** Improving the Participation Rate for Comprehensive Medication Reviews Through Enhancing Part D Beneficiaries' Understanding of the Service. Presented at AMCP 25th Annual Meeting & Expo, April 3-5, 2013, San Diego, California. Recipient of Honorable Mention for Best Research Presentation in the Resident/Fellow Category.
77. **Segal R.** Examining Alternate Standardized Scripts to Improve Comprehensive Medication Review Participation Rate. Presented at AMCP 25th Annual Meeting & Expo, April 3-5, 2013, San Diego, California.
78. **Segal R.** Improving the Participation Rate for Comprehensive Medication Reviews. Presented at the AMCP 24th Annual Meeting, April 20, 2012, San Francisco.
79. **Segal R.** Cancer Advocacy in Africa: Developing a Program Evaluation. 1st Cancer Advocacy for African Countries. November 2011, Cairo, Egypt.
80. **Segal R.** Disagreements on Medication Nonadherence Between Prescription Claims and Patient Reports from Medication Therapy Management Interviews. Presented at the AMCP 23rd Annual Meeting & Showcase, April 2011, Minneapolis, Minnesota.

81. **Segal R.** Comparison of Suboptimal Treatments Identified from Claims Data Alone with a Medication Therapy Management Patient Interview. Presented at the AMCP 23rd Annual Meeting & Showcase, April 2011, Minneapolis, Minnesota.
82. **Segal R.** Disagreements Between Claims Data and Patient Reports from Medication Therapy Management Interviews when Identifying Medication-Related Problems. Presented at the AMCP 23rd Annual Meeting & Showcase, April 2011, Minneapolis, Minnesota.
83. Improving accuracy of a home medication list through telephone interviews. Presented at the 45th ASHP Midyear Clinical Meeting, Anaheim, December 2010.
84. Adherence Perspectives in Florida: Focus on the Advanced Aged Patient. Jacksonville, FL, December 3, 2009.
85. Economic Cost of Diabetes Among Medicaid Patients, University of Alabama, Birmingham, Nov 15, 2007.
86. Economic Cost of Diabetes among Medicaid Patients, University of Pennsylvania, September 2007.
87. Implementing Disease Management Initiatives in Medicaid Programs. University of Pennsylvania, August 12, 2007.
88. A Diabetes II cost model to project savings accruing from disease management programs. Eighth International Symposium on Pharmaceutical Sciences. June 16, 2006, Ankura, Turkey.
89. Economic Cost of Diabetes Among Medicaid Patients, Massachusetts General Hospital, Boston, October 20, 2006.
90. Pharmacist and Pharmacy Technician Opinions on the Appropriateness of Community Pharmacy Technician Functions Poster Presentation 2006 ASHP Summer Meeting in Orlando, Florida, June 26, 2006.
91. Florida Pharmacy Technician Credentials. APhA-APRS Economic, Social, and Administrative Sciences Contributed Papers Poster Session at the APhA2007 Annual Meeting & Exposition. Mar 16-19, 2007, Atlanta, GA., JAPhA, 47(2), 263.
92. Projected Cost Savings Comparison to Third Party Payers for the Year Following Generic Simvastatin and Pravastatin Availability in the U.S. To be presented at the International Society of Pharmacoeconomics and Outcomes Research Meeting in Alexandria, VA, May 2006.

93. Florida Pharmacy Technician Credentials. To be presented at the American Pharmacists Association Meeting, Atlanta, 2006.
94. Pharmacist and pharmacy technician opinions on the appropriateness of community pharmacy technician functions. Presented at the 2006 ASHP Summer Meeting in Orlando, Florida, June 25-28, 2006.
95. The economic evaluation of Diabetes II disease management programmes. World Congress of Pharmacy and Pharmaceutical Sciences, September 4, 2005, Cairo.
96. The impact of glycemic control on the incidence of diabetic complications. Tenth Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research. May 15-18, 2005 Washington, DC. Value in Health 2005; 8(3):256.
97. The American Medical Association's Guidelines on Gifts to Physicians: An Assessment of Intent to Comply. Presented at the American Pharmacists Association Meeting, Orlando, April 2005.
98. Diabetes Care in a Medicaid Disease Management Program. Presented at the American Diabetes Association Meeting 64th Scientific Session, Orlando, June 2004.
99. The Effect of Cholesterol Lowering Therapy on Coronary Heart Disease in a Diabetic Medicaid Population. Presented at the Southern Pharmacy Administration Conference, Ft. Lauderdale, June 2004.
100. Evaluation of Pharmacist Interventions in Diabetic Patients from Rural Community Health Centers. Presented at the Southern Pharmacy Administration Conference, Ft. Lauderdale, June 2004.
101. Evaluation of Pharmacist Interventions In Diabetic Patients From Rural Community Health Care Centers. Presented at the APhA Annual Meeting in Seattle, March 29, 2004. Winner of the APhA-APRS 'Postgraduate Best Paper Award' in the Clinical Sciences section.
102. Evaluation of Pharmacist Interventions in Diabetic Patients from Rural Community Health Centers. Presented at the International Society for Pharmacoeconomics and Outcomes Research, 2004.
103. The Economic Impact of Glycemic Control as Measured by Glycosylated Hemoglobin: A Systematic Review of Diabetes Outcomes Studies. Presented at the International Society for Pharmacoeconomics and Outcomes Research, 2004.
104. Evaluation of Pharmacist Interventions in Diabetic Patients from Rural Community Health Centers. Presented at the 38th ASHP Midyear Clinical Meeting, New Orleans, December 2003.

105. Taylor MD, Greenwood K, Johns T, Schmidt JC, Segal R, Hatton R. Cost-minimization analysis of a pharmacist-directed pantoprazole intravenous to oral dosage form conversion program. Presented at ISPOR. 2003.
106. Managing Diabetes in Florida-Based Community Health Centers. Presented at the 37th ASHP Midyear Clinical Meeting Atlanta, December 11, 2002.
107. How Do Prescribers Cope With Ambiguity When Prescribing New Chemical Entities? Presented at the 24th Annual Meeting of the Society for Medical Decision Making, Baltimore, Maryland, October 21, 2002.
108. Pharmacoepidemiologic Methods To Detect Preventable Adverse Drug Events, Presented at the ISPE Scientific Program, Edinburgh, Scotland, August 20, 2002.
109. Stimulated Report of In-hospital Medication Errors of Omission and Commission Utilizing Personal Digital Assistants (PDAs), The Pharmacy Administration Conference. Presented at the Drug Information Association 38th Annual Meeting in Chicago, IL, June 16-20, 2002
110. Stimulated Report of In-hospital Medication Errors of Omission and Commission Utilizing Personal Digital Assistants (PDAs) The Pharmacy Administration Conference. Presented at the Pharmacy Administration Conference in Monroe, LA, June 7, 2002.
111. Managing Diabetes in Community Health Centers. Presented at the APhA Annual Meeting in Philadelphia, March 17-18, 2002.
112. Impact of Patient Persuasion on Physician Antibiotic Prescribing for Viral Infections. Presented at the APhA Annual Meeting in Philadelphia, March 17-18, 2002.
113. Test of a pharmacist model of perceived responsibility for drug therapy outcomes. Presented at the APhA Annual Meeting in Philadelphia, March 17-18, 2002.
114. Screening Tools for Medication Errors in Hospitals. Joint Annual Meeting of the Association for Applied Human Pharmacology and ACCP, Partenkirchen, Germany, January 2002.
115. Introduction of a systematic approach to detect and reduce preventable adverse drug events. Presented at the 36th ASHP Midyear Clinical Meeting in New Orleans, December 2001.
116. Preventable adverse drug events in hospitals: medications, types of errors and outcomes. Presented at the American College of Clinical Pharmacy Meeting in Tampa, FL, October 2001.

117. Outcomes Assessment of Low Molecular Weight Heparin Therapeutic Interchange. Presented at the 35th ASHP Midyear Clinical Meeting in Las Vegas, December 2000.
118. Impact of an Employer-Sponsored Intervention on Diabetes Health Outcomes, Resource Utilization, and Workplace Productivity. Presented at the 35th ASHP Midyear Clinical Meeting in Las Vegas, December 2000.
119. Designing an Electronic Patient Record with Multiple Real-Time Decision Support Modules for Managing Diseases. To be presented at the American Medical Informatics Association in Los Angeles, November 2000.
120. Outcomes Research and Disease Management. Presented at the Pharmaceutical Outcomes Researcher Meeting; Fort Lauderdale, FL, May 17, 2000.
121. An Electronic Patient Record with Multiple Real-Time Decision Support Modules for Managing Diseases Presented at the American Medical Informatics Association in Boston, May 2000.
122. Air Force Pharmacists' Professional Decisions and Values, Communication Apprehension and Pharmaceutical Care Behaviors. Presented at the American Pharmaceutical Association Meeting in Washington D.C., March 2000.
123. Progress toward Achieving the Healthy People 2000 Objectives: The Case of the State Of Florida. Presented at the American Pharmaceutical Association Meeting in Washington D.C., March 2000.
124. Use of Behavioral Risk Factor Surveillance System (BRFSS) To Identify Pharmaceutical Care Needs: A Case Study of Florida. Presented at the American Pharmaceutical Association Meeting in Washington D.C., March 2000.
125. Progress towards the Provision of Pharmaceutical Care Services. Presented at the American Pharmaceutical Association Meeting in Washington D.C., March 2000.
126. Collaborative Drug Therapy Management and the Pharmacist. Invited presentation to the Florida Pharmacy Association Regulatory & Law Conference, Sarasota FL, December 4, 1999.
127. Collaborative Drug Therapy Management and the Pharmacist. Invited presentation to the Florida Pharmacy Association Regulatory & Law Conference, Ft Lauderdale FL, October 2, 1999.
128. Opportunities in the Medicines Use Process for Improving Health: Collaborative Practices. Invited Presentation to the Florida Board of Health Task Force on Collaborative Practice, Tallahassee FL, August 1999.

129. Improving the Medicines Use Process: Drug Therapy Management. Invited Presentation to the Florida Board of Pharmacy Task Force on Drug Therapy Management, Orlando FL, July 1999.
130. Effects of Asthma Patient Characteristics on Hospital Costs and ICU Admissions. Presented at the ASHP Annual Meeting, June 1999.
131. An Exploratory Study of Asthma Patient Characteristics on Hospital Costs and ICU Admissions. Presented at the Drug Information Association Meeting, Baltimore, MD, June 1999.
132. Randomized Evaluation of a Disease Management Program for Dyspepsia in a Managed Care Setting. Presented at the International Society for Pharmacoeconomics and Outcomes Research Meeting, Arlington VA, May 24, 1999.
133. A Randomized Trial of a Disease Management Program for Dyspepsia in a Managed Care Setting. Presented at the Digestive Disease Weekly (DDW) meeting, Orlando, FL, May 18, 1999.
134. Overview of Outcomes Research, Disease Management, and Population-Based Decision Making. Presented at The Practical Outcomes Researcher Workshop. Jacksonville, FL, April 23, 1999.
135. Development and Evaluation of a Unique Partnership in Health and Disease Management. Invited Presentation at ASHP's Conference on Disease Management, Chicago IL, October 5, 1998.
136. Conference of Pharmacoeconomics and Decision Making. Workshop facilitator. Orlando FL, April 4-5, 1998.
137. Methods for Developing and Implementing Practice Guidelines/Pathways. ESAS Research Roundtable Leader. American Pharmaceutical Association Meeting in Miami Florida, March 22, 1998.
138. Provider Profiling. Invited presentation at the American Drug Utilization Review Meeting in Albuquerque, New Mexico, February 1998.
139. What is Disease State Management? Presented at the 22nd Clinical Pharmacy Symposium at Florida A&M University, February 1998.
140. Pharmaceutical Care. Presented at the 22nd Clinical Pharmacy Symposium at Florida A&M University, February 1998.
141. Pharmaceutical Outcomes Research. Presented at the 22nd Clinical Pharmacy Symposium at Florida A&M University, February 1998.

142. HCFA Proposals on Diabetes Education and Implications for Florida. North Carolina Center for Pharmaceutical Care, January 1998.
143. A Training Program to Implement Pharmaceutical Care Practice in Community Pharmacy. Presented at the Federation Internationale Pharmaceutique Section of Community Pharmacy in Vancouver, Canada, September 1997.
144. Disease Management - The Ultimate Outcomes-Based Physician Compensation and Management System. Presented at The National Managed Health Care Congress (NMHCC), Atlanta GA, June 24, 1997.
145. Overview of Outcomes Research, Disease Management, and Population-Based Decision Making. Presented at the ASHP Annual Meeting, Minneapolis MN, June 1997.
146. Unique Partnership in Health Management and Disease Management: Implementing Practice Guidelines in a Managed Care Organization. Presented at the Associates of Clinical Pharmacology meeting, Atlanta, GA, May 19, 1997.
147. Pharmacoeconomic Evaluation of Mycophenolate Mofetil in Solid Organ Transplant Patients. Presented at the American College of Clinical Pharmacy, April 8, 1997.
148. Asthma and the Pharmacist's Involvement in Patient Care. Presented at the North Central Florida Society of Health-System Pharmacists/Alachua County Association of Pharmacists Meeting, Gainesville, March 22, 1997.
149. Understanding the Selection of Performance Measurement Tools. 14th AHSR (Academy for Health Services Research and Health Policy) Annual Meeting, Chicago, June 1997.
150. Designing Disease Management Systems for a Changing Health Care Environment. Presented at the University of Florida Departments of Pharmacodynamics & Pharmaceutics Seminar Series, January 23, 1997.
151. A Cognitive Approach to Understanding Performance Monitoring in Clinical CQI. Presented at the National Forum on Quality Improvement in Health Care Scientific Symposium, New Orleans, December 7, 1996.
152. The Development and Evaluation of the Hypertension Temporal Orientation (HTO) Scale. Presented at the 12th Annual American Public Health Association (Medical Care Section), New York, November 19, 1996.

153. Partnership in Quality Improvement: Focus on GI Disease. Presented at the 3rd Annual Congress on Health Outcomes & Accountability (The Zitter Group), San Francisco, November 14, 1996.
154. Disease Management: Applications to Acid Peptic Disorders. Presented to the Nontraditional Pharm.D. Program, Gainesville, October 19, 1996.
155. Applying the Principles of Pharmaceutical Care to the Patient with Diabetes. Presented as a Consensus Symposium in New Horizons in Diabetes Care for *Pharmacy Practice Management Quarterly*, Bahamas, October 6, 1996.
156. Disease Management in Integrated Health Systems. Presented at Medical Grand Rounds at Presbyterian Hospital, Charlotte, NC, March 13, 1996.
157. Pharmacoeconomics of Acid Peptic Disorders from a Disease Management Perspective. Presented to the Carolina Medical Center, Divisions of Internal Medicine and Family Medicine, Charlotte NC, March 12, 1996.
158. Cultural Differences in Health Perceptions and the Mediating Role of Hypertension Temporal Orientation. Presented at the American Pharmaceutical Association 143rd Annual Meeting, Nashville TN, March 10, 1996.
159. Implementing a Partnership in Disease Management. Presented at the Astra Merck Annual Meeting, Orlando, FL, February 28, 1996.
160. The Relationship of Expectations and Perceived Quality with Consumers' Evaluation of Pharmaceutical Information Services. American Marketing Association 1996 Winter Marketing Educators' Conference, February 1996, Hilton Head, SC.
161. Issues in Disease Management. Presented to the University of Florida College of Pharmacy Advisory Board, September 1995.
162. Pharmacoeconomics of Acid Peptic Disorders from a Disease Management Perspective. Presented to the Indian River Pharmaceutical Association, Ft. Pierce, FL, September 12, 1995.
163. Disease Management and Outcomes Research in Integrated Health Care Systems. Invited presentations to the medical and pharmacy staff at Hill AFB, Utah, June 1995.
164. Evaluation of the Therapeutic Modalities in the Treatment of Acid-Peptic Disorders. Invited presentation to the Florida Health Care Plan (FHCP) HMO, Daytona Beach, FL, May 24, 1995.

165. Therapeutic Outcomes Monitoring. Invited presentation at the 40 annual Ohio Pharmaceutical Seminar, Columbus, OH, April 24, 1995.
166. Pharmaceutical Care: A Method for Improving Health and Reducing Costs. Invited presentation at Rx for Change Symposium, Connecticut Hospital Association at Aetna Middletown Conference Center, April 25, 1995.
167. The Theory of Pharmacists' trying to provide Pharmaceutical Care. Presented at the American Pharmaceutical Association Meeting, Orlando, FL, March 1995.
168. The Effect of Health Perceptions on Use of Antihypertensive Medications and Use of Home Remedies. Presented at the American Pharmaceutical Association Meeting, Orlando, FL, March 1995.
169. Disease Management in Gastroesophageal Reflux Disease. A CME video prepared by the Medical College of Virginia, 1995.
170. Performance Evaluation in Health Care and Pharmacy. Invited presentation at the 29th Annual ASHP Midyear Clinical Meeting, Miami Beach, FL, December 9, 1994.
171. Cost of Managing Peptic Acid Disease in Ambulatory Settings. Presented as a Command Performance Presentation at the 29th Annual ASHP Midyear Clinical Meeting, Miami Beach, FL, December 5, 1994.
172. Innovations in Florida's Health Care Delivery System. Invited presentation at the 23rd Annual Pharmacy Law and Management Conference in Orlando, FL, November 20, 1994.
173. Pharmacoeconomic Considerations of Peptic Acid Disease. Presented at the AAPS Annual Meeting, San Diego, CA, November 8, 1994.
174. Outcomes Analysis in Peptic Acid Disease. Invited presentation to the Astra/Merck Business Unit in La Jolla, CA, November 5, 1994.
175. Implementing Pharmaceutical Care: From Theory to Practice. Invited Keynote presentation at the Congr s Des Pharmaciens du Qu bec in Montr al Canada, October 1994.
176. Looking Beyond Drug Costs: Examining Peptic-Acid Disorders. Invited presentation at the Florida Society of Hospital Pharmacists Annual Meeting in Orlando, August 19, 1994.
177. Implementation of Pharmaceutical Care in Ambulatory Settings. Invited presentation at the 4th Pan Pacific Asian Congress on Clinical Pharmacy, Jakarta, Indonesia, July 12, 1994.

178. Pharmaceutical care. Invited presentation at the Wyoming Pharmaceutical Association meeting in Gillette, June 18, 1994.
179. Pharmaceutical Care Paradigm. Invited keynote presentation at a symposium entitled "The Changing Face of Pharmacy" for pharmaceutical advisors in NHS, London England, May 9, 1994.
180. The Importance of Pharmaceutical Care to Patient Outcomes. Invited presentation at Hospital Report Cards and Patient Outcomes Symposium sponsored by Florida Hospital Association and Florida Society of Hospital Pharmacists, Orlando FL, April 28, 1994.
181. Costs of Asthma Hospitalization in a University Hospital. Presented at the American Academy of Allergy & Immunology Meeting, Anaheim CA, March 8, 1994.
182. Creating Disease-Specific Guidelines for Implementing Pharmaceutical Care. Presented at the 28th Annual ASHP Midyear Clinical Meeting, Atlanta, GA, December 10, 1993.
183. Development and Validation of a Behavioral Pharmaceutical Care Questionnaire. Presented at the 28th Annual ASHP Midyear Clinical Meeting, Atlanta, GA, December 8, 1993.
184. The Realities of Implementing a CQI Project in an Inpatient Setting. Presented at the 28th Annual ASHP Midyear Clinical Meeting, Atlanta, GA, December 10, 1993.
185. Clinical and Fiscal Issues in the Selection of Modalities in the Treatment of Peptic Acid Diseases. Invited presentation to the Texas Society of Hospital Pharmacists and the University of Texas at Austin, November 1993.
186. Assessing the Impact of Medications on Quality of Life. Presented at the American Public Health Association Meeting in the Pharmacoeconomics and outcomes research forum, San Francisco, October 1993.
187. Problems Managing HIV Drug Therapy. Presented at the American Public Health Association Meeting in the ATOD Session, San Francisco, October 1993.
188. Presider and Discussant in the Medical Care Contributed Paper Session on Hospital Strategies in a Changing Health Care System and Presider in the Medical Care Session III at the American Public Health Association Meeting, San Francisco, October 1993.
189. Evaluation of Therapeutic Modalities in the Treatment of Peptic Acid Disorders in Ambulatory Patient Populations in Florida. Invited presentation at the FSHP 27th Annual Meeting, August 1993.

190. Research to Determine the Value of Cognitive Services. Invited presentation at the Arthur E. Schwarting Pharmacy Practice Symposium at the University of Connecticut, May 1993.
191. Evaluation of a Drug Use Evaluation Data Collection Instrument. Presented at the 27th Annual ASHP Midyear Clinical Meeting, Orlando, FL, December 10, 1992.
192. Pharmaceutical Care: Implementing Pharmaceutical Care and Therapeutic Outcomes Monitoring. Invited presentation at XVI Pharmacy Days, The Finnish Centre for Continuing Pharmaceutical Education, Helsinki, November 1992.
193. Research Problems in Pharmaceutical Care. Invited presentation in Research Seminar, University of Kuopio, Kuopio Finland, November 1992.
194. Pharmacy Education and Community Practice in America. Invited presentation to participants in Orion Pharmaceutica Forum, Stockholm, November 1992.
195. Post Exchange Actions of Elderly Consumers in the High Blood Pressure Drug Market. Presented at the Association for Consumer Research Meeting, Vancouver, British Columbia, Canada, October 9, 1992.
196. Drugs in the Elderly. Invited presentation to approximately 60 elderly persons at the Atrium, Gainesville, FL, September 1992.
197. Final Analysis of a Multicenter Drug Use Evaluation and Cost Analysis of I.V. H₂-receptor Antagonists and Preliminary Description of Omeprazole Utilization in an HMO Population in Florida". Invited presentation to Florida Society of Hospital Pharmacists Annual Meeting, August 21, 1992.
198. The Medical Literature: Reading and Understanding Clinical Studies. Invited presentation at the GI Mid-Year Meeting for Merck Health Services Associates, Minneapolis, MN, July 28, 1992.
199. New Therapies for the Treatment of Peptic Acid Disease: Quality and Costs Considerations. Invited presentation in Tucson, AZ on May 26, 1992, and Phoenix, AZ on May 27, 1992.
200. Socioeconomic Issues about Biotechnology. Invited presentation at the Rho Chi Colloquium on Biotechnology Issues, University of Florida, March 30, 1992.
201. Drug Use Evaluation: Clinical and Economic Considerations. Invited presentation in Graduate Seminar Series, The Ohio State University, February 11, 1992.
202. Drug Use Evaluation: From Drug Utilization Review to Continuous Quality Improvement. Invited presentation at the Merck GI Health Services Associates Meeting, Palm Springs, CA, January 6, 1992.

203. Histamine-2 Receptor Antagonist Multi-Center DUE Research. Invited presentation at the Merck GI Health Services Associates Meeting, Palm Springs, CA, January 7, 1992.
204. Multi-Center Drug Use Evaluation and Cost Analysis of Intravenous Histamine-2 Receptor Antagonists. Presented at the 26th Annual ASHP Midyear Clinical Meeting, New Orleans, LA, December 10, 1991.
205. Drug Use Evaluation: Clinical and Fiscal Considerations in H₂-RAs. Invited presentation at the New Mexico Society of Hospital Pharmacists Symposium, December 3, 1991.
206. Prescribed Medicines: Usage and Expenditure Patterns for the Elderly Population in Four Central Florida Counties. Presented at the American Public Health Association Annual Meeting in Atlanta, Ga., November 13, 1991.
207. Parenteral Histamine-2 receptor Antagonists: Multicenter Drug Use Evaluation and Cost Analysis Study. Invited presentation at the Florida Society of Hospital Pharmacists Annual Meeting in Orlando, FL., August 1991.
208. Patient Satisfaction/Dissatisfaction and Post-Purchase Actions in the High-Blood Pressure Prescription Drug Market: A Preliminary Report. Presented at the 1991 Conference on Consumer Satisfaction/Dissatisfaction and Complaining Behavior, Salt Lake City, Utah, June 24-26, 1991.
209. Multidisciplinary Survey to Determine Attitudes on the Conduct of Drug-Related Clinical Research Projects. Presented at the 1991 ASHP Annual Meeting in San Diego, CA., June 1991.
210. Assessing the Impact of an Entertainment News Broadcast on the Use of Theophylline. Presented at the National Council for Patient Information and Education Meeting in Washington D.C., April 1991.
211. Invited Speaker on "Writing a report for publication" at the 25th Annual ASHP Midyear Clinical Meeting (with C. Brink, M. Nahata, D. Rich, L Trissel), December 6, 1990.
212. Pharmaceutical Technology Assessment: Trends and Opportunities (Roerig Division of Pfizer Pharmaceuticals). Conference moderator and speaker, San Antonio, Texas, June 9, 1990, and November 1990.
213. Relationship between Medication Compliance and Patient Outcomes in Kidney Transplant Patients. Presented at the 1990 ASHP Annual Meeting at the Foundation Grants Forum in Boston, June 5, 1990.
214. A Cost Analysis of Medication Use by the Elderly Population in Four Central Florida Counties. Presented at the Southern Gerontological Society Meeting in Orlando, FL, March 23, 1990.

215. Employee Prescription Programs in Ohio Hospitals. Presented at the 1989 ASHP Midyear Clinical Meeting in Atlanta, December 4, 1989.
216. Managed Care and Pharmacy: Opportunities for Pharmacy. Invited presentation at the University of Florida College of Pharmacy Development Advisory Board Meeting, May 19, 1989.
217. Characteristics of Medication Administration Errors. Presented at the 1988 ASHP Midyear Clinical Meeting in Dallas, December 6, 1988.
218. Survey of Critical-Care Pharmacy Services. Presented at the 1988 ASHP Midyear Clinical Meeting in Dallas, December 6, 1988.
219. Establishing the Link between Patient Medication Compliance and Patient Outcome in Kidney Transplant Patients. Presented at the 1988 ASHP Midyear Clinical Meeting in Dallas, December 7, 1988.
220. Moderator, The Impact of Cost Containment on Hospital Pharmacy Operations. An 8-hour Conference sponsored by a grant from the Upjohn Company, September 1988.
221. Moderator, Mail Order Prescription Services, 33rd Annual Ohio Pharmaceutical Seminar, April 13, 1988.
222. Developing Effective Pharmacy Communications. A 30-hour program presented with R. Brusadin, R. Buerki, and J. Visconti in Hawaii, February 9-16, 1988. Sponsored by a grant from Hoechst-Roussel Pharmaceuticals.
223. Impact of Medication Counseling by Pharmacists in the Veterans Administration Setting. Presented at the COSHP Contributed Papers Meeting in Columbus, OH, February 1988.
224. Quality Assurance for a Clinical Pharmacy Patient Education Program on Pain Management. Presented at the COSHP Contributed Papers Meeting in Columbus, OH, February 1988.
225. Quality Assurance for a Clinical Pharmacy Patient Education Program on Pain Management. Presented at the 22nd Annual ASHP Clinical Midyear Meeting in Atlanta, GA, December 9, 1987.
226. Impact of a Clinical Pharmacist on Antibiotic Prescribing: A Controlled Multicenter Study. Presented as a management case study at the 22nd Annual ASHP Clinical Midyear Meeting in Atlanta, GA, December 10, 1987.
227. Impact of Medication Counseling by Pharmacists in the Veterans Administration Setting. Presented at the 22nd Annual ASHP Midyear Clinical Meeting in Atlanta, GA, December 7, 1987.

228. National Survey of Intravenous Admixture Practices. Presented at the 22nd Annual ASHP Midyear Clinical Meeting in Atlanta, GA, December 7, 1987.
229. Development of an Adverse Drug Reaction Reporting System. Presented as a management case study at the 22nd Annual ASHP Midyear Clinical Meeting, December 8, 1987.
230. Cost Comparison of Drug Preparation and Administration Using Five Available Infusion Systems. Presented at the 22nd Annual ASHP Clinical Midyear Meeting in Atlanta, GA, December 8, 1987.
231. Comparison of Ibuprofen, Placebo, and Fentanyl as Analgesic Components of General Anesthesia in Ambulatory Surgery. Presented at the 22nd Annual ASHP Clinical Midyear Meeting in Atlanta, GA, December 9, 1987.
232. Midwest Conference on The Changing Health Care: It's Impact on Pharmacy and the Pharmaceutical Industry in Indianapolis, IN. Served as a Workshop Facilitator for the program on "Managed Health Care," November 11-14, 1987.
233. Medication Awareness Program. A 30-minute television program directed to consumers by the Council on Health Information with Timothy Moore (Senior Director of Pharmacy Services at Ohio State University Hospitals), September 1987.
234. Impact of a Clinical Pharmacist on Antibiotic Prescribing: A Controlled Multi-Institutional Study. Presented at the 44th ASHP Annual Meeting, Washington, D.C., June 1, 1987.
235. Current Practices for Preparing Intravenous Admixtures in a Hospital Pharmacy Setting. Presented at the 44th ASHP Annual Meeting, Washington, D.C., June 2, 1987.
236. Marketing Your Pharmacy. A 20-hour program presented with Rinaldo Brusadin in Barbados, February 11-15, 1987. Sponsored by a grant from Searle.
237. A National Audit of Antineoplastic Handling Practices and Attitudes. Presented at the 21st Annual ASHP Midyear Clinical Meeting in Las Vegas, Nevada, December 11, 1986.
238. Ritzman L and Segal R. Mobile Pharmacy and the Elderly: A Feasibility and Evaluation Study. Podium Presentation at the West Virginia University & Mylan Pharmaceuticals Undergraduate Research Seminar, November 1986.
239. The Impact of a Flexitime Program on Pharmacy Technicians' Work-Related Measures. Presented at the 43rd ASHP Annual Meeting in Denver, Colorado. June 1986.

240. A National Audit of Intravenous Admixture Practice. Presented as Research-in-Progress at the 43rd ASHP Annual Meeting in Denver, Colorado. June 1986.
241. Invited speaker and resource person on Pharmaceutical Assistance on behalf of the Ohio Department on Aging at the 1986 Governor's Conference on Aging, Columbus, June 18, 1986.
242. Moderator, Prescription to OTC Switch at the 31st Annual Ohio Pharmaceutical Seminar, April 16, 1986.
243. Consultant Pharmacists' Recommendations: From Theory to Practice. Invited Presentation at the University of Toledo College of Pharmacy Research Seminar Series, April 9, 1986.
244. Professional Attributes: A Comparison of Pharmacists from Three Practice Settings. Presented at the American Pharmaceutical Association 133rd Annual Meeting in San Francisco, CA, March 1986.
245. A Study of the Impact of a Flextime Program on Work-Related Measures. Presented at the COSHP Contributed Papers Meeting in Columbus, OH, January 1986.
246. Educational Needs for Assistant Directors of Hospital Pharmacy. Presented at the Federation Internationale Pharmaceutique Section of Hospital Pharmacists in Montreal, Canada, September 1985.
247. Participant in a special invitational conference titled "Directions for Clinical Practice in Pharmacy" sponsored by ASHP Research and Education Foundation at Hilton Head Island, February 1985.
248. Payn D and Segal R. An Evaluation of Independent Community Pharmacists' Beliefs Concerning the Advertising of Professional Services. Presented at the West Virginia University & Mylan Pharmaceuticals Undergraduate Research Seminar, October 1984.
249. Invited speaker at a Food and Drug Administration Consumer Exchange Meeting on 'Medicine and the Elderly' in Columbus, June 6, 1984.
250. Basic Statistical Analyses Used in Drug Trials and Their Interpretation. Presented at the Ohio Society of Hospital Pharmacy Annual Meeting, Cincinnati, Ohio, April 28, 1984.
251. How Physicians Choose the Drugs They Prescribe. Invited speaker at the 10th Banff Seminar of the Canadian Society of Hospital Pharmacists in Banff, Alberta, Canada, March 1984.
252. Knowledge of Prescribers' Beliefs and Values Can Help Predict Prescribing Behavior. Presented at the Ohio Society of Hospital Pharmacists Meeting in Columbus, OH, October 1983.
253. A Cognitive Model of Drug Prescribing. Presented at the ASHP Midyear Clinical Meeting in Atlanta, December 1983.

254. Knowledge of Prescribers' Beliefs and Values Can Help to Predict Prescribing Behavior. Presented at the ASHP Midyear Clinical Meeting in San Francisco, December 1980.

PUBLICATIONS (* denotes student author)

1. Nelson, T., Wilkie, D.J., Yao, Y., Segal, R., DeVaughan-Circles, A., Weaver, M., Donahoo, W.T., Goins, R.T., Manson, S.M., Legaspi, A.B., & Scarton, L. Medication adherence, determinants of health, and A1C levels among American Indian adults with type 2 diabetes receiving Tribal health services. *The Science of Diabetes Self-Management and Care*. (Submitted 12-14-23).
2. Nelson, T., Wilkie, D.J., Yao, Y., Segal, R., DeVaughan-Circles, A., Weaver, M., Donahoo, W.T., Goins, R.T., Manson, S.M., Legaspi, A.B., & Scarton, L. Electronic health record-derived social determinants of health and association with glycemic status among American Indian adults with type 2 diabetes within a Tribal health center, 2020-2021. *American Journal of Public Health*. (Submitted 12-14-23).
3. Alalwan AA,* Friedman J, Park H, Segal R, Brumback B, Hartzema A. Effectiveness and Safety of Warfarin After Bariatric Surgery in Atrial Fibrillation and Venous Thromboembolism Patients: A Propensity Score Analysis. *Obesity Surgery* (submitted).
4. Wallace JL,* **Segal R**, Zeigler ML, Wheat LD, Forrest JR, Kim J, Vargas AJ, Odedina FT, Wilson SR, Angaran DM. Impact of Integrating Community Health Workers into the Medication Use Process in a Culturally Diverse Population with Poorly Controlled High Blood Pressure. Submitted.
5. Kim J,* **Segal R**, Hartzema AG. Comparison of cost of and adherence to infliximab in patients with rheumatoid arthritis between hospital-owned outpatient practices and physician offices. Medical Care (submitted).
6. Kim J,* Brumback B, **Segal R**, Wang GP, Hartzema AG. Metformin and risk of developing rheumatoid arthritis: a retrospective cohort study. Arthritis and Rheumatology (submitted).
7. Knox C,* Hampp C, Brumback B, **Segal, R**, Winterstein AG. Epidemiology of Pre-existing Diabetes in Pregnancy among Medicaid Patients in 29 US States from 2000-2006. BMC Pregnancy and Childbirth, (submitted).
8. Eworke E,* **Segal R**. Treatment utilization associated with nontuberculous mycobacteria in patients with cystic fibrosis. Journal of Clinical Pharmacy and Therapeutics, (submitted).
9. Liu W,* Antonelli P, Dahm P, Gerhard T, Delaney J, **Segal R**, Crystal S, Winterstein A. Comparative ototoxicity of phosphodiesterase type 5 inhibitors to treatment of erectile dysfunction. The Laryngoscope (submitted).

10. Onyenwenyi A,* Winterstein A, **Segal R**, Schuster J, Lipowski E. Off-Label Prescribing of Anticonvulsant Drugs-National Pattern 1993-2005, (submitted).
11. Segal R and Salinas M. Evaluating Cancer Advocacy Programs. Handbook for Prostrate Cancer Advocacy: Principles & Best Practice. Odedina FT (editor). CaPTC Publication Series, #101. 2023. In press.
12. Park H, Brown C, Wilson DL, Huang P, Hernandez-Con P, Horne P, Goodin A, Joseph A, Segal R, Carbera R, Cook RL. Clinician barriers, perceptions, and practices in treating patients with hepatitis C virus and substance use disorder. *Preventive Medicine Reports* 2023. 32: 102138. DOI: 10.1016/j.pmedr.2023.102138
13. Wilson D,* Kimberlin C, Brushwood D, **Segal R**. Florida Pharmacy Technician Credentials. Research in Social & Administrative Pharmacy, in press.
14. Reams, R.R., Odedina, F.T., Carpten, J.D., Redda, K., Stern, M.C., Krieger, J.L., Aparicio, J., Hensel, B., Askins, N., Abreu, A., Adams, A., Agyare, E., Ali, J., Allen, J.M., Aló, R., Baezconde-Garbanati, L., Brant, J., Brown, C.P., Buxbaum, S.G., Cohen, P., Cozen, W., Ezenwa, M.O., Falzarano, S. Fillingim, R.B., Flores-Rozas, H., Fredenburg, K.M., George, T., Han, B., Huang, Y., Hughes Halbert, C., Kiros, G-E., Lamango, N.S., Lee, J-H., Lyon, D.E., Mitchell, D.A., Mochona, B., Nieva, J.J., Offringa, I.A., Okunieff, P., Parker, A., Rhie, S.K., Richey, J.M., Rogers, S.C., Sahlia, B., Schmittgen, T.D., Segal, R., Setiawan, V.W., Smith, U., Su, L., Suther, S., Trevino, J., Velazquez-Villarreal, E.I., Webb, F.J., Wu, A.H., Yao, Y., & Wilkie, D.J. Florida-California Cancer Research, Education and Engagement (CaRE²) Health Equity Center: Structure and Initial Outcomes. *Cancer Control*. 2023 Jan-Dec 30: 10732748231197878. doi: 10.1177/10732748231197878.
15. Scarton, L., Nelson, T., Yao, Y., DeVaughan-Circles, A., Legaspi, A.B., Donahoo, W.T., Segal, R., Goins, R.T., Manson, S.M, & Wilkie, D.J. Association of Medication Adherence with HbA1c Control among American Indian Adults with Type 2 Diabetes Using Tribal Health Services. *Diabetes Care*. 2003 46(6): 1245-1251.
16. Scarton L, Nelson T, Yingwei Y, **Segal R**, Donahoo WT, Goins RT, DeVaughan-Circles A, Manson SM, Wilke DJ. Medication Adherence and Cardio-Metabolic Control Indicators among American Indian Adults Receiving Tribal Health Services: Protocol for a Longitudinal Electronic Health Records Study. *JIMR Research Protocols*, 2023, 11(10). Doi: 10.2196/39193 PMID: 36279173.
17. Alalwan AA,* Feedman J, Park H, **Segal R**, Brumback B, Hartzema AG. Comparative Safety of Sleeve Gastrectomy and Roux-en-Y: A Propensity Score Analysis. *World J Surg*. 2022 Jul 15. doi: 10.1007/s00268-022-06664-0). PMID: 35840690
18. Costales B,* Boemmel-Wegmann S,* Winterstein A, and **Segal R**. Clinical Conditions and Prescription Drug Utilization among Early Medical Marijuana Registrants in Florida. *Journal of Psychoactive Drugs*.\, 2021. <https://www.tandfonline.com/doi/full/10.1080/02791072.2020.1864069>
19. Jeon N,* Park H, **Segal R**, Brumback B, Winterstein AG. Non-steroidal anti-inflammatory drug-associated acute kidney injury: Does short-term NSAID use pose a risk in hospitalized patients? *European Journal of Clinical Pharmacology*, 2021 Mar 27. doi: 10.1007/s00228-021-03121-0. Online ahead of print. PMID: 33772627.

20. Alalwan AA,* Friedman J, Park H, **Segal R**, Brumback BA, Hartzema AG. US national trends in bariatric surgery: A decade of study. Surgery (2021) DOI:<https://doi.org/10.1016/j.surg.2021.02.002>.
21. Brown JD, Costales B, van Boemmel-Wegmann S, Goodin AJ, **Segal R**, Winterstein AG. Characteristics of older adults who were early adopters of medical cannabis in the Florida medical marijuana use registry. Journal of Clinical Medicine, 2020, 9(1166), <https://doi.org/10.3390/jcm9041166>.
22. Olasupo O,* **Segal R**, Brown J. Missed Opportunities for Pneumococcal Vaccinations in High Risk and Older Adults in the United States. Journal of Infection and Public Health, 2020. <https://doi.org/10.1016/j.jiph.2019.06.010>
23. **Segal R**, Angaran DM, Odedina FT, Zeigler ML, Wallace JL. Opportunities and Responsibilities for Pharmacists to Improve Their Effectiveness in Addressing Medication Adherence through Culturally Sensitive Collaborations with Community Health Workers. Journal of American Pharmacists Association, 2020, 60(4): e25-e30, <https://doi.org/10.1016/j.japh.2020.02.023>
24. Shen Y,* Lo-Ciganic W, **Segal R**, Goodin AJ. Prevalence of substance use disorder and psychiatric comorbidity burden among pregnant women with opioid use disorder in a large administrative database, 2009-2014. Journal of Psychosomatic Obstetrics & Gynecology, 2020, doi: 10.1080/0167482X.2020.1727882.
25. Young-Rock H, Hincapie-Castillo J, Xie Z, **Segal R**, Mainous A. Socioeconomic and Demographic Characteristics of US Adults Who Purchase Prescription Drugs From Other Countries. JAMA Network Open. 2020;3(6):e208968. doi:10.1001/jamanetworkopen.2020.8968
26. Grundmann O, **Segal R**, Pullo J, Davis L, Felix-Irizarry Y, Da Silva L, Holets T. The pharmacist as an LGBTQ+ Ally. American Journal of Pharmaceutical Education, 2020, DOI: 10.5688/ajpe7835.
27. Wheat L, Roane TE, Connelly A, Zeigler M, Wallace J, Kim JH, **Segal R**. Using a Pharmacist-Community Health Worker Collaboration to Address Medication Adherence Barriers. Journal of American Pharmacists Association, 2020, 60(6): 1009-1014.
28. Dawwas G,* Dietrich E, Winterstein A, Winchester DE, **Segal R**, Park H. Comparative Effectiveness of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome: A retrospective cohort analysis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2019; Jul 22. doi: 10.1002/phar.2311.
29. Naboulsou M,* Hardin H, Behar-Horenstein L, Su Y, **Segal R**. Impacting Student Self-Efficacy and Beliefs of Medication Therapy Management Through a 2-Week Elective. American Journal of Pharmaceutical Education, 2019, 83(5): 741-746.
30. Knox C,* Hampp C, Palmsten K, Zhu Y, Setoguchi S, Brumback B, **Segal R**, Winterstein AG. Validation of mother-infant linkage using Medicaid Case ID variable within the Medicaid Analytic eXtract (MAX) database. Pharmacoepidemiology & Drug Safety, 2019, 28(9): 1222-1230.
31. Murimi I,* Ghambaryan A, Decker R, Lu X, **Segal R**, Loyo-Berrios N, Marinac-Dabic D, Hartzema AG. FDA coauthors DEPI/OSB/CDRH-Ghambaryan, Loyo-Berrios, Marinac –Dabic. Association between Recombinant Human Bone Morphogenetic Proteins and Post-Operative Opioid Use in Lumbar Fusion

- Procedure Patients: A Propensity-Score Matched Analysis. *World Neurosurgery*. 2018 Dec;120:e42-e52. doi: 10.1016/j.wneu.2018.07.125.
32. Liu W,* Antonelli P, Dahm P, Gerhard T, Delaney J, **Segal R**, Crystal S, Winterstein A. Risk of sudden sensorineural hearing loss in adults using phosphodiesterase type 5 inhibitors: population-based cohort study. *Pharmacoepidemiology & Drug Safety*, 2018; 1-9.
 33. Liu X,* Carney P, Bussing R, Segal R, Cottler L, Winterstein A. Stimulants Do Not Increase the Risk of Seizure-Related Hospitalizations in Children with Epilepsy . *J Child Adolesc Psychopharmacol*. 2018 Mar;28(2):111-116. doi: 10.1089/cap.2017.0110. Epub 2017 Oct 13.
 34. Jiang X,* Xiao H, **Segal R**, Mobley W, Park H. Trends in readmission rates, hospital charges and mortality for patients with chronic obstructive pulmonary disease (COPD) in Florida from 2009 to 2014. *Clinical Therapeutics*, 2018, 8(4): 1-14.
 35. Wen X,* Hartzema A, Delaney JA, Brumback B, Liu X, Egerman R, Roth J, **Segal R**, Meador KJ. Combining Adverse Pregnancy and Perinatal Outcomes for Women Exposed to Antiepileptic Drugs During Pregnancy, Using a Latent Trait Model. *BMC Pregnancy and Childbirth*. 2017; 17:10.
 36. Mansoor M,* Elgendy IY, **Segal R**, Hartzema A. Duration of reproductive years and the risk of cardiovascular events in older women: Insights from the National Health and Nutrition Examination Survey (NHANES). *Journal of Women's Health (Larchmt)*. 2017:Oct, 26(10):1047-1052.
 37. Jeon N,* Staley B, Johns T, Pflugfelder G, Brumback B, **Segal R**, Winterstein A. Identifying and characterizing preventable drug events for prioritizing pharmacist interventions in hospitals. *American Journal of Health-System Pharmacy*. 2017, 74 (21) 1774-1783; DOI: <https://doi.org/10.2146/ajhp160387>.
 38. Miguel A,* Hall A, Liu W,* Garrett J,* Ballew A, Yang T,* **Segal R**. Improving Comprehensive Medication Review Acceptance by Using a Standardized Recruitment Script: A Randomized Control Trial. *J Manage Care Spec Pharm*. 2017; 23(1):13-21.
 39. Mansoor H,* Elgendy I, **Segal R**, Bavry AA, Bian, J. Risk prediction model for in-hospital mortality in women with ST-elevation myocardial infarction: A machine-learning approach. *Heart & Lung – The Journal of Acute and Critical Care*, 2017 Nov-Dec;46(6): 405-411.
 40. Liu X,* Carney P, Bussing R, **Segal R**, Cottler L, Winterstein A. Trends in antiepileptic drug use in children and adolescents with epilepsy. *Pediatric Neurology*, <http://dx.doi.org/10.1016/j.pediatrneurol.2017.05.016>. 2017;74:32-40.
 41. Linden S,* Bussing R, Kubilis P, Gerhard T, **Segal R**, Shuster J, Winterstein A. Risk of Suicidal Events with Atomoxetine Compared to Stimulant Treatment: A Cohort Study. *Pediatrics*, 2016, 137(5), e20153199.
 42. Chen CY,* Bussing R, Hartzema AG, Shuster JJ, **Segal R**, Winterstein AG. Stimulant Use Following the Publicity of Cardiovascular Safety and the Introduction of Patient Medication guides. *Pharmacoepidemiology and Drug Safety*, November 2015, DOI: 10.1002/pds.3894.

43. Segal R. Program evaluation. Chapter 11. In: *Handbook for Prostate Cancer Advocacy: Principles & Best Practices* (FT. Odedina, ed.). Orlando: CaPTC, (2016).
44. Liu X,* Carney P, Bussing R, Segal R, Cottler L, Winterstein AG. Safety of Stimulants in Children with Epilepsy: a retrospective Cohort Study. 32nd International Conference of Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland; August 25-28, 2016. *Pharmacoepi Drug Saf* 2016;25(Suppl. 3):34.
45. Choi, YY,* Eworuke E, Segal, R. What explains the different rates of human papillomavirus vaccination among adolescent males and females in the United States. *Papillomavirus Research*, 2016, 2: 46-51.
46. Ali A,* Hartzema A, Winterstein A, **Segal R**, Lu X, Hendeles L. Application of multicategory exposure marginal structural models to investigate the association between long-acting beta-agonists and prescribing of oral corticosteroids for asthma exacerbations in the Clinical Practice Research Datalink. *Value in Health* <http://dx.doi.org/10.1016/j.jval.2014.11.007>.
47. Mukherjee K, **Segal R**. Discussions with healthcare providers about prostate-specific antigen testing: evidence from the Behavioral Risk Factor Surveillance System in the USA. *Journal of Pharmaceutical Health Services Research*. (2015) DOI: 10.1111/jphs. 12078.
48. Lee C,* **Segal R**, Kimberlin C, Smith WT, Weiler RM. Pharmacist's perspective on providing care when patients engage in unhealthy behaviors. *Journal of the American Pharmacists Association*, 2014, 54(2):e67-e70.
49. Lee C,* **Segal R**, Kimberlin C, Smith WT, Weiler, RM. Reliability and validity for the measurement of moral disengagement in pharmacists. *Research in Social & Administrative Pharmacy*, 2013, DOI:10.1016/j.sapharm.2013.06.006.
50. Odedina FT, Asante-Shongwe K, Kandusi EJ, **Segal R**, Pressey S, Reams RR, Simons VH. The African Cancer Advocacy Consortium: Shaping the Path for Advocacy in Africa. *Infectious Agents and Cancer*, 2013, 8 (Suppl): S8.
51. **Segal R**, Odedina FT, Pressey S. Proceedings of the International Workshop on Cancer Advocacy for African Countries. *Infectious Agents and Cancer*, 2011, 8 (Suppl): S1.
52. Robinson JD, Segal R, Lopez LM, Doty RE. Impact of a Pharmaceutical Care Intervention on Blood Pressure Control in a Chain Pharmacy Practice. *Annals of Pharmacotherapy*, 2010, 44: 88-96.
53. Odedina FT, Shavers VL, **Segal R**, Pressey S (Eds). The Science of Global Cancer Disparities in Black Men. *Infectious Agents and Cancer*, 2011: 6 (Suppl 2): 11 (<http://www.infectagentscancer.com/supplements/6/S2>).
54. Mukherjee K,* **Segal R**, Kenny LW Kauf T. Effects of Change in Price of Medical Care on Daily Living of People in the United States. *Journal of Pharmaceutical Health Services Research*, 2011, 2(4):205-210.

55. Wen S,* Meador KJ, Loring DW, Eisenschenk S, **Segal R**, Hartzema A. Is Antiepileptic Drug Use Related to Depression and Suicidality Among Patients with Epilepsy? Epilepsy and Behavior, 2010, 19: 494–500.
56. Wilson D,* Kimberlin C, Brushwood D, Segal R. Investigation of the Potential Effects of Registration Requirements on Florida Pharmacy Technician Credentials. The Journal of Pharmacy Technology, 2010, 26: 116-22.
57. Mueller M,* Kimberlin C, **Segal R**, Brushwood D, Graham-Pole J. Family caregiver quality of life: the impact of demands of caregiving, medication administration and stress in a pediatric oncology setting. Oncology Nursing Forum, 2009, 36(1).
58. Wilson D,* Kimberlin C, Brushwood D, **Segal R**. Constructs Underlying Community Pharmacy Technician Functions. J Am Pharm Assoc, 2007, 47(5): 588-98.
59. Pinto S,* Lipowski E, **Segal R**, Kimberlin C, Algina J. Physicians' Intent to Comply with the American Medical Association's Guidelines on Gifts from the Pharmaceutical Industry. J Med Ethics, 2006, 33: 313-319.
60. Gandhi PK,* Spooner JJ, Grosebeck JM, Segal R. Projected Cost Savings Comparison to Managed Care Organizations for the Year Following Generic Simvastatin and Pravastatin Availability in the U.S. Value in Health, 2007, 10(3):2-19.
61. White A,* Odedina F, Xiao H, Campbell E, and **Segal R**. The Economic Burden of End-Stage Renal Disease with Hyperphosphatemia: A Study of Florida Medicaid. Disease Management & Health Outcomes, Volume 14, Number 2, 2006, 8: 99-106.
62. Planes LG,* Kimberlin CL, **Segal R**, Brushwood DB, Hepler CD, Schlenker BR. A pharmacist model of perceived responsibility for drug therapy outcomes. Social Science & Medicine, 2005, 60: 2393–2403.
63. Maue S,* **Segal R**, Kimberlin C, Lipowski EE. Predicting physician guideline compliance: An assessment of motivators and perceived barriers. Am J Managed Care, 2004, 10: 383-391.
64. Orrick JJ, **Segal R**, Johns TE, Russell W, Wang F, Yin DD. Resource Use and Cost of Care for Patients Hospitalized with Community-Acquired Pneumonia (Impact of Adherence to IDSA Guidelines). Pharmacoeconomics, 2004, 22 (11): 751-757.
65. Robinson D, **Segal R** Winterstein A, Annis L, Pinto S. Impact of Point-of-care Information about Medications on Health Outcomes in Community Health Centers. Bureau of Primary Health Care, 2004, HRSA.

66. Lipowski EE, **Segal R**, "An evaluation of enhancements in electronic technology for prescribers in Florida Medicaid program" Florida Center for Medicaid and the Uninsured. Agency for Health Care Administration, 2004.
67. Pinto S,* Segal R, Winterstein AG, Annis L, Robinson D, Yates D, Pederson L, Willis M. Evaluation of Pharmacist Interventions in Diabetic Patients from Rural Community Health Centers. Value in Health, 01/2004, 7(3):337.
68. Winterstein AG, Taylor MD, Hartzema AG, **Segal R**. The economic impact on glycemic control as measured by glycosylated hemoglobin- a systematic review of diabetes outcomes studies. Agency for Health Care Administration. March 2004.
69. Lipowski EE, **Segal R**. Identification and treatment of Medicaid recipients with Hepatitis C. Report to the Agency for Health Care Administration. June 2004.
70. Ofman JJ, **Segal R**, Russell WA, Cook D, Sandhu M, Maue S, Lowenstein E, Purfarzib R, Weingarten S. A randomized trial of an acid-peptic disease management program in a managed care environment. Am J Managed Care, 2003, 9:425-433.
71. Enders J,* Hoffman L, Pippins R, **Segal R**. Impact of a high utilization management program in reducing unnecessary prescription claims. Am J Health-Systems Pharm, 2003, 60:371-374.
72. Kanjanarat P,* Winterstein AG, Johns TE, Gonzalez-Rothi R, Hatton RC, **Segal R**. Nature of preventable adverse drug events in hospitals: a literature review. Am J Health-Systems Pharm, 2003, 60:1750-9.
73. Hepler CD and Segal R. Preventing medication errors and improving drug therapy outcomes: A management systems approach. Boca Raton FL: CRC Press, 2003, 520 pages, ISBN: 0-8493-1576-X.
74. Hoffman L, Enders J, Luo J, **Segal R**, Pippins J, **Kimberlin C**. Impact of an antidepressant management program on medication adherence. Am J Managed Care, 2003, 9:70-80.
75. Hoffman L, Enders J, Luo J, Pippins J, **Segal R**. Reducing claims for prescription drugs with a high potential for abuse. Am J Health Syst Pharm . 2003 Feb 15;60(4):371-4. doi: 10.1093/ajhp/60.4.371.
76. Greenwood K, Johns T, Schmidt JC, Segal R, Hatton R. Cost-minimization analysis of a pharmacist-directed pantoprazole intravenous to oral dosage form conversion program. Value in Health, 2003, 6(3): 249.

77. Winterstein A, Hatton R, Gonzalez R, Johns T, **Segal R**. Identifying Clinically Significant Preventable Adverse Drug Events through a Hospital's Database of Adverse Drug Reaction Reports. Am J Health-Systems Pharm, 2002, 59:1742-9.
78. Hendeles, L, **Segal R**. Pharmacoeconomic studies of asthma controller medications; marketing gimmick or icing on the cake? Pharmacotherapy, 2002, 22(2):131-133.
79. Hunt MA, **Segal R**, Lopez L, Sullivan J. Dalteparin for enoxaparin interchange: Chart review shows promising clinical, economic outcomes. Formulary, 2001, 36:747-751.
80. Buring S, Russell W, Meyer KM, **Segal R**. *ASHP Therapeutic Position Statement on the recognition and treatment of Helicobacter pylori disease*. Am J Health-System Pharm, 2001, 58:331-337.
81. Maue SK* and **Segal R**. Application of Pharmacoeconomics and Decision Analysis to Gastrointestinal Disorders Within a Broad-Based Disease Management Program. *Introduction to Pharmacoeconomics* (R. Vogenberg, ed.). New York: McGraw Hill, 144-178, 2001.
82. Benn DK, Kostewicz SH, Dankel DD, Segal R, Schmidt SO, and Chardon Z. Designing an electronic patient record with multiple real-time decision support modules for managing diseases. Proc AMIA Symp, 2000: 1168.
83. **Segal R**, Wang F. Influencing Physician Prescribing. PPMQ, 1999, 19:3: 30-50.
84. Thornhill LP,* Nayak RA, Berardo DH, Gums JG, Russell W, **Segal R**. An assessment of osteoporosis risk factors: a computer-aided strategy to identify and evaluate patient risk factors using a clinic database. Third National Women's Health & Research, 1998, 201-205.
85. Nau DP,* Grainger-Rousseau TJ, Doty RE, Hepler CD, Ried LD, **Segal R**. Preparing Pharmacists for Pharmaceutical Care. J Am Pharm Assoc, 1998, 38(6):644-5.
86. Aversa S,* Kimberlin C, **Segal R**. The Medication Attribution Scale: Perceived Effects of Antiretrovirals and Quality of Life. Quality of Life Research, 1998, 7:205-214.
87. Grainger-Rousseau TJ,* Miralles MA,* Hepler CD, **Segal R**, Doty RE, Ben-Joseph R. Therapeutic Outcomes Monitoring: Application of Pharmaceutical Care Guidelines to Community Pharmacy. JAPhA, 1997, NS37 (6):647-661.
88. **Segal R**. Applying the Principles of Pharmaceutical Care to the Patient with Diabetes. In Wilson AL , Mehra IV. *Managing the Patient with Diabetes*. Aspen Publishers, Inc. 1997, 43-48.

89. Brown CM* and **Segal R**. The Development and Evaluation of the Hypertension Temporal Orientation (HTO) Scale. Ethnicity & Disease, 1997, 7:41-54.
90. **Segal R**. Applying the Principles of Pharmaceutical Care to the Patient with Diabetes. PPMQ, 1997, 17(2):47-53.
91. Odedina F*, Hepler CD, **Segal R** and Miller D. The Pharmacist's Implementation of Pharmaceutical Care (PIPC) Model. Pharmaceutical Research, 1997, 135-144.
92. **Segal R**. Therapeutic Outcomes Monitoring. In: *Escovitz A, Pathak DS (eds.) Health Outcomes and Pharmaceutical Care*. Binghamton, NY: Haworth Press, 1996; pp. 193-199.
93. Brown CM* and **Segal R**. Ethnic Differences in Temporal Orientation and Its Implications for Hypertension Management. Journal of Health and Social Behavior, 1996, 37(4):350-361.
94. **Segal R**. Therapeutic Outcomes Monitoring: A Method for Implementing Pharmaceutical Care. Journal of Research in Pharmaceutical Economics, 1996, 8(1):193-198.
95. **Segal R**, Russell WL, Ben-Joseph R, Mansheim B. Cost of Acid Peptic Disorders in a Managed Care Organization. Clinical Therapeutics, 1996, 18:319-333.
96. Halberg DL*, Russell WL, Hatton RC, **Segal R**, Guyton T, Paulus D. Pharmacoeconomic Evaluation of Anesthesia in Ambulatory Surgery: Comparison of Desflurane to Isoflurane and Propofol. Pharmacy Practice Management Quarterly, 1996, 16(2):71-85.
97. Brown CM* and **Segal R**. The Effects of Health and Treatment Perceptions on the Use of Prescribed Medication and Home Remedies among African American and White American Hypertensives. Social Science and Medicine, 1996, 43:906-917.
98. Odedina F*, **Segal R**, Hepler CD, Lipowski E, Kimberlin C. Changing Pharmacists' Practice Pattern: Pharmacists' Implementation of Pharmaceutical Care Factors. Journal of Social and Administrative Pharmacy, 1996, 13(2):74-88.
99. Odedina F* and **Segal R**. Behavioral pharmaceutical care scale for measuring pharmacists' activities. American Journal of Health-System Pharmacists, 1996, 53:855-65.
100. Grainger-Rousseau T* and **Segal R**. Economic, Clinical and Psychosocial Outcomes of Home Infusion Therapy: A Review of Published Studies (adapted from PPMQ, 1995:15(1): 57-77). Continuing Education Series in Pharmacy & Managed Care, 1996, 3(5):8-12.

101. Odedina F, **Segal R** and Hepler CD. Providing Pharmaceutical Care in Community Practice: Differences between Providers and Non-Providers of Pharmaceutical Care. Journal of Social and Administrative Pharmacy, 1996, 12:170-180.
102. **Segal R** and Russell WL. Cost/outcomes management in the hospital (audiocassette). Dialogues in Hospital Pharmacy. Cortlandt Communications, Ossining NY.1995; 1(3).
103. **Segal R**, Ried LD, Mackowiak J. Cost of Asthma Illnesses: Emergency Department Visits without Admission. Pharmacy Practice Management Quarterly, 1995, 15(3):72-82.
104. Ben-Joseph R*, **Segal R**, Russell W, Oh T. Evaluating the Value, Accuracy, and Operational Feasibility of DUE Criteria. Hospital Formulary, 1995, 30:280-283.
105. Grainger-Rousseau T* and **Segal R**. Economic, Clinical and Psychosocial Outcomes of Home Infusion Therapy: A Review of Published Studies. Pharmacy Practice Management Quarterly, 1995, 15(1): 57-77.
106. Pathak DS, Kucukarslan S, **Segal R**. Explaining patient satisfaction/dissatisfaction in high blood pressure prescription drug market: an application of equity theory and disconfirmation paradigm. Journal of Consumer Satisfaction, Dissatisfaction and Complaining Behavior, 1994, 7:53-73.
107. **Segal R**, Oh T, Ben-Joseph, Russell WL. A pharmacoeconomic analysis of IV H₂-receptor antagonists use in 40 Hospitals. Hospital Formulary, 1994, 29:379-91.
108. **Segal R**, Russell WL, Oh T, Ben-Joseph R. Use of I.V. Cimetidine, Ranitidine, and Famotidine in 40 Hospitals in Southeastern United States. American Journal of Hospital Pharmacy, 1993, 50:2077-81.
109. Hartzema AG, Porta MS, Tilson HH, Ben Joseph R, Segal R, Russell WL. Risk for adverse events among patients receiving intravenous histamine₂-receptor antagonists. Annals of Pharmacotherapy, 1993, 27 (12): 1532-1537.
110. Ben-Joseph R*, **Segal R**, Russell WL. Risk for Adverse Events Among Patients Receiving I.V. Histamine₂ Receptor Antagonists. Annals of Pharmacotherapy, 1993, 27:1532-7.
111. Pathak DS, Kucukarslan S, Sirdeshmukh, **Segal R**. The Vulnerable Consumer in the High Blood Pressure Drug Market: Bothered but Satisfied? Advances in Consumer Research, 1993, 20:245-252.

112. **Segal R.** A Framework for Evaluating the Work of Pharmacists. Topics in Hospital Pharmacy Management. 1992;12(1):9-19. Republished in Issues in Pharmacy Practice Management, Wilson AL, Editor. Gaithersburg MD: Aspen Publishers, Inc., pp. 130-140, 1997.
113. Hospital Pharmacy Management: Forms, Checklists and Guidelines. Gaithersburg, MD.: Aspen, 1992. Contributor and member of Editorial Board.
114. Sirdeshmukh D^{*}, Pathak DS, Kucukarslan S, **Segal R**, Kier KL, Aversa SL. Patient Satisfaction/Dissatisfaction and Post Exchange Actions in the High Blood Pressure Prescription Drug Market: A Preliminary Report. Journal of Consumer Satisfaction, Dissatisfaction and Complaining Behavior, 1991, 4:84-92.
115. Thornton JP^{*}, Goff DA, **Segal R**, and Guy JT. Impact of a Clinical Pharmacist on Antibiotic Prescribing: A Multicenter Trial. Journal of Pharmacy Technology, 1991, 7(Sept/Oct):195-200.
116. **Segal R.** What are the fiscal implications of pharmaceutical biotechnology and its impact on the healthcare marketplace. FSHP Digest, 1991, 3(5):7.
117. Tschepik W^{*}, **Segal R**, Sherrin TP, Schneider D, and Hammond R. Therapeutic Risk Assessment Model for Identifying Patients with Adverse Drug Reactions. American Journal of Hospital Pharmacy, 1990, 47:330-334.
118. Funk PA^{*}, **Segal R**, and Pathak DS. Selection of Pharmacy Providers and Other Primary Care Providers by Young Families. Journal of Pharmaceutical Marketing & Management, 1990, 4(3):41-59.
119. **Segal R**, Wantz DL, and Brusadin RA. Pharmacists' Decision Making in the Selection of Generic Pharmaceuticals. Journal of Pharmaceutical Marketing & Management, 1989, 4(1):75-91.
120. Dasta JF, **Segal R**, and Cunningham A. National Survey of Critical-Care Pharmaceutical Services. American Journal of Hospital Pharmacy, 1989, 46:2308-2312.
121. Carter EA^{*} and **Segal R**. Factors Influencing Pharmacists' Selection of Their First Practice Setting. American Journal of Hospital Pharmacy, 1989, 46:2294-2300.
122. **Segal R** and Sheridan DJ. Pharmacist Selection Methods Used by Pharmacy Managers. American Journal of Hospital Pharmacy, 1989, 46:1824-6.
123. Escovitz A and **Segal R**. Proceedings of a Symposium: The Impact of Cost Containment on Hospital Pharmacy Operations. (Guest Editors.) Journal of Research in Pharmaceutical Economics, 1989, 1(2).

124. Swanson K* and **Segal R**. Book Review: "How to Evaluate Progressive Pharmaceutical Services, by McKay AB, Hepler CD and Knapp DA." Topics in Hospital Pharmacy Management, 1989, 9(2):73-74.
125. **Segal R** and Nicely PG. Needs Assessment and the Cardiac Rehabilitation Patient: A Focus on Medication Teaching. Journal of Pharmacy Technology, 1989, 5:57-62.
126. Rupp MT* and **Segal R**. Confirmatory Factor Analysis of a Professionalism Scale in Pharmacy. Journal of Social and Administrative Pharmacy, 1989, 6(1):31-38.
127. Sheridan DJ* and **Segal R**. Criteria for Staff Pharmacist Selection in Ohio. American Journal of Hospital Pharmacy, 1989, 46:295-301.
128. **Segal R** and Pathak DS. Formulary Decision Making: Identifying Factors That Influence P&T Committee Drug Evaluations. Hospital Formulary, 1988, 23:174-8.
129. **Segal R** and Grines LL. Prescribing Authority for Pharmacists as Viewed by Organized Pharmacy, Organized Medicine, and the Pharmaceutical Industry. Drug Intelligence and Clinical Pharmacy, 1988, 22:241-6.
130. Rupp MT*, **Segal R**, and Pathak DS. Program Planning of a Biomedical Communications Center: An Implementation-Oriented Approach. Journal of Biocommunications, 1988, (Winter):2-8.
131. **Segal R**, Grines LL, and Pathak DS. Opinions of Pharmacy, Medicine, and Pharmaceutical Industry Leaders about Hypothetical Therapeutic-Interchange Legislation. American Journal of Hospital Pharmacy, 1988, 45:570-7.
132. Kodyalam SR*, **Segal R**, and Pathak DS. Anatomy of Today's Sales Training Programs. Medical Marketing and Media, 1988, 23(3):8-16.
133. Berry LL*, **Segal R**, Sherrin TP, and Fudge KA. Sensitivity and Specificity of Three Methods of Detecting Adverse Drug Reactions. American Journal of Hospital Pharmacy, 1988, 45:1534-39.
134. **Segal R**, Swanson T, and Clark J. Impact of Medication Counseling by Pharmacists in the Veterans Administration Setting. Washington D.C.: ASHP Foundation, Inc., 1988.
135. Kodyalam SR*, **Segal R**, and Rutherford G. Pharmacist Rehabilitation: The National Experience and the Ohio Program. Ohio Pharmacist, 1987, 36(2):44-47.

136. **Segal R**, Jacobs EW, and Funk PA. Professional Attitudes of Ohio Pharmacists Working in Three Practice Settings. American Journal of Hospital Pharmacy, 1987, 44:795-799.
137. **Segal R**, Kodiyalam SR, and Rutherford G. Pharmacist Rehabilitation Program: The Role of the Pharmacist as an Intervenor. Ohio Pharmacist. 1987;36(3):81-83.
138. **Segal R**, Kodiyalam SR, and Rutherford G. Pharmacist Rehabilitation Program: The Role of the Pharmacist as an Intervenor. OSHP Bulletin, 1987, 7(3):4.
139. Gregoire RE^{*}, **Segal R** and Hale K. Handling Antineoplastic Drug Admixtures at Cancer Centers: Practices and Pharmacist Attitudes. American Journal of Hospital Pharmacy, 1987, 44:1090-1095.
140. **Segal R** and Pathak DS. An Evaluation of Multi-Attribute Models for Physician Acceptance of Pharmacist-Initiated Drug Therapy Recommendations. Journal of Geriatric Drug Therapy, 1987, 1(3):49-64.
141. Birdwell SW^{*}, **Segal R**, Reardon G, and Pathak DS. Development of a Data Base to Assist in the Dispensing Fee Determination for Participating Pharmacy Providers in the Ohio Medicaid Program. Ohio Pharmacist, 1987, 36(5):144-6.
142. Brzozowski DF^{*}, Hale KM, **Segal R**, and Mirtallo JM. Pharmacists' Opinions about Compliance with Recommendations for Intravenous Admixture Practices. American Journal of Hospital Pharmacy, 1987, 44:2077-84.
143. **Segal, R**. Proceedings on The Changing Health Care Environment: It's Impact on Pharmacy and the Pharmaceutical Industry. Workshop Section Report on Managed Health Care. 1987, (November 11-14):77-80.
144. **Segal R** and Smith DP. Pharmacists' Beliefs and Values about Advertising Patient-Oriented Services. Journal of Health Care Marketing, 1986, 6(1):35-41.
145. **Segal R** and Pathak DS. Influencing Physician Acceptance of Consultant Pharmacists' Recommendations. The Consultant Pharmacist, 1986, 1:129-133.
146. Lunik MC^{*} and **Segal R**. Cost Benefit and Cost-Effectiveness Analysis: A Bibliography for Pharmacists. Hospital Pharmacy, 1986, 21:1072-1075.
147. **Segal R** and Pathak DS. Predicting the Formulary Decision Making of Pharmacy and Therapeutics Committee Members. Washington D.C.: ASHP Research and Education Foundation, Inc., 1985.

148. **Segal R.** Designing a Pharmacy Survey. Topics in Hospital Pharmacy Management, 1985, 5(1):37-45.
149. **Segal R** and Hepler CD. Drug Choice as a Problem-Solving Process. Medical Care, 1985, 23:967-976.
150. Payn DA* and **Segal R.** Professional Pharmacy Services - Which Ones to Advertise. NARD Journal, 1984, (Sept):141-142.
151. Jacobs E and **Segal R.** 1984 Ohio Pharmacist Salary and Fringe Benefit Survey: Salary Report of Part-Time Hospital Pharmacists. OSHP Bulletin, 1984, 4(3).
152. Jacobs E and **Segal R.** 1984 Ohio Pharmacist Salary and Fringe Benefit Survey: Fringe Benefit Report of Full-Time Hospital Pharmacists. OSHP Bulletin, 1984, 4(4).
153. Jacobs E and **Segal R.** 1984 Ohio Pharmacist Salary and Fringe Benefit Survey: Report of Part-Time Hospital Pharmacists. Ohio Pharmacist, 1984, 4(5).
154. Jacobs E and **Segal R.** 1984 Ohio Pharmacist Salary and Fringe Benefit Survey: Salary Report of Part-Time Community Pharmacists. Ohio Pharmacist, 1984, 33(6):186-188.
155. Jacobs E and **Segal R.** 1984 Ohio Pharmacist Salary and Fringe Benefit Survey: Fringe Benefit Report of Full-Time Community Pharmacists. Ohio Pharmacist, 1984, 33(7):213-215.
156. Jacobs E and **Segal R.** 1984 Ohio Pharmacist Salary and Fringe Benefit Survey: Report of Part-Time Community Pharmacists. Ohio Pharmacist, 1984, 33(8):244-245.
157. Hepler CD and **Segal R.** Motivating Pharmacy Personnel: A Managerial Framework. Topics in Hospital Pharmacy Management, 1983, 3(May):10-36.
158. **Segal R** and Hepler CD. Prescribers' Beliefs and Values as Predictors of Drug Choices. American Journal of Hospital Pharmacy, 1982, 39:1891-7.
159. **Segal R.** Why Worry About Job Satisfaction. American Journal of Hospital Pharmacy, (Letter) 1981, 38:168.
160. Hepler CD, **Segal R**, and Freeman RA. How Physicians Choose the Drugs They Prescribe. Topics in Hospital Pharmacy Management, 1981, 1(Nov):23-44.

161. Hepler CD and **Segal R.** Another Day, Another Dollar - A Primer on Motivation: It Seems Like Nobody Wants to Really Work Anymore. Pharmacy Management, 1979, 151:214-5,218.

162. **Segal R.** Therapeutic Update. Iowa Pharmacist, 1978, 33(2):20.

PATENTS

Pharmaceutical Care Plan, Monitoring, Consulting and Reimbursement Software. UF#-10443, copyright. Patent filed, 2001.

RESEARCH GRANTS FUNDED OR PENDING (Principle or Co-Principle Investigator unless indicated)

Pending:

Florida Minority Cancer Research and Training Center: Feasibility Studies, NCI, PAR-14-152, pending.

Funded:

2022-2026 Scarton, L. (PI), DeVaughan-Circles, A., Donahoo, W.T., Goins, R.T., Segal, R., Yao, Y., & Wilkie, D.J. Medication Adherence and Cardio-Metabolic Control Indicators among Adult American Indians Receiving Tribal Health Services. National Institute of Nursing Research 1R01NR020386-01, \$1,975,628.

CDK 4/6 Inhibitors Use Among Metastatic Breast Cancer Patients: Early Discontinuation And Management Of Adverse Events, AWD09582, Diaby (PI), Segal (co-PI), \$184,638, Pfizer, Inc.

Improving the Effectiveness of Medication Therapy Management. CDC 1305 Grant: State Public Health Actions to Prevent and Control Diabetes, Heart Disease, Obesity, and Associated Risk Factors and Promote School Health. CDC/Department of Health, Segal (PI), \$800,000, 2019-2023.

The 6th Biennial Science of Global Prostate Cancer Disparities in Black Men of African Ancestry," NIH/NCI Center for Global Health R13CA254395 and 1R13CA265019-01, \$20,000 (Odedina PI, Segal Co-PI), 2020-2021.

Correlates of quality of life in men with prostate cancer in Nigeria. Principles & Practices of Behavioral Research for Cancer Prevention and Control in West Africa: An Africa Behavioral Research Center Program. NCI Center for Global Health, NCI CGH Cancer Research Training Grant. Segal (Co-I) 2018-19.

Assessing the impact of interventions performed by community health workers collaborating with pharmacists in improving medication use and adherence. CDC 1305 Grant: State Public Health Actions to

Prevent and Control Diabetes, Heart Disease, Obesity, and Associated Risk Factors and Promote School Health. CDC/Department of Health, Segal (PI), \$46,009, 2018.

Diabetes Self-Management Education Via Telehealth Feasibility Study SOW16-042, Segal PI, Zeigler Co-PI, \$72,000, 2018.

Identifying Medication Use Problems and Improving Minority Health through Community Health Workers, AFPE Gateway to Research Award to Jordan Wallace, PharmD student, and Richard Segal, Advisor, \$5,000, 2018-19.

Improving Health Living Behaviors and Outcomes in Native Americans. CDC 1305 Grant: State Public Health Actions to Prevent and Control Diabetes, Heart Disease, Obesity, and Associated Risk Factors and Promote School Health. CDC/Department of Health, Segal (PI), \$80,000, 2017-2018.

State Public Health Collaborative to improve cardiovascular health outcomes. Association of State and Territorial Health Officials. \$122,290 to Florida Department of Health, \$60,000 Subaward to Segal (PI), 2017-18.

Evaluating the outcome of an interprofessional collaborative practice model involving community health workers and pharmacists in improving outcomes in hypertension and diabetes mellitus. CDC 1305 Grant: State Public Health Actions to Prevent and Control Diabetes, Heart Disease, Obesity, and Associated Risk Factors and Promote School Health. CDC/Department of Health, Segal (PI), \$150,000, 2017-2018.

Assessing the impact of interventions performed by community health workers collaborating with pharmacists in improving medication use and adherence. CDC 1305 Grant: State Public Health Actions to Prevent and Control Diabetes, Heart Disease, Obesity, and Associated Risk Factors and Promote School Health. CDC/Department of Health, Segal (PI), \$178,000, 2016-2017.

Science of Global Prostate Cancer Disparities," NIH/NCI R13 1R13CA210494-01, (Odedina PI, Segal Co-PI), \$80,000, 2016-17.

Improving medication-related outcomes by having community health workers collaborate with pharmacists. CDC 1305 Grant: State Public Health Actions to Prevent and Control Diabetes, Heart Disease, Obesity, and Associated Risk Factors and Promote School Health. CDC/Department of Health, Odedina (PI) and Segal (Co-PI), \$128,000, 2015-2016.

Training Community Health Workers to Improve Medication-Related Outcomes for Poorly Controlled Patients with Hypertension or Diabetes. CDC 1305 Grant: State Public Health Actions to Prevent and Control Diabetes, Heart Disease, Obesity, and Associated Risk Factors and Promote School Health. CDC/Department of Health, Odedina (PI) and Segal (Co-PI), \$111,000, 2014- 2015.

3rd Biennial Science of Global Prostate Cancer Disparities in Black Men, NIH/NCI R13 1R13CA189451-01, (Odedina PI, Segal Co-PI), \$60,000, 2014.

Knowledge of Prostate Cancer Uncertainty among Black Men, P20 NIH/NCI, Odedina (PI), Segal PI on Behavioral Science Core, Funded for \$233,127, 2014 - present.

Development of a Complexity Score to identify hospitalized patients at high risk for preventable adverse drug events. ASHP Foundation, (Winterstein PI, Segal Co-Inv).

Research Starter Grant to study and improve medication adherence for Dr. Anna Hall, PhRMA, \$50,000 Segal is mentor, 2014.

Training Community Health Workers to Improve Medication-Related Outcomes for Poorly Controlled Patients with Hypertension or Diabetes. CDC/Department of Health, Odedina (PI) and Segal (Co-PI), \$111,000, 2013-2014.

Cancer Advocacy for Low Resource Countries, Prostate Net, AORTIC, \$20,000 (Odedina PI and Segal, Co-PI).

The 2nd Biennial Science of Global Prostate Cancer Disparities in Black Men, NIH/NCI R13, 1R13CA171754-01 (Odedina PI, Segal PI), \$20,000, 2012.

“Impact of Medication Therapy Management services by Community Health Workers,” CDC/Department of Health, Odedina (PI) and Segal (Co-PI), \$70,658, 2012-13.

“The International Conference on Cancer Advocacy for African Countries (CAAC),” NIH/NCI R13, (Odedina PI, Segal PI), \$17,840 with additional funding by University of Florida and Prostate Net, total \$80,000.

“Evaluation of Medication Therapy Management (MTM),” Wellcare Health Plans, (Angaran, PI, Segal Investigator and Director of Research), \$1,420,845, 7/1/12-6/30/13.

“Evaluation of Medication Therapy Management (MTM),” Wellcare Health Plans, (Angaran, PI, Segal Investigator and Director of Research), \$1,286,283, 7/1/11-6/30/12.

Evaluating the impact of community health workers in the management of chronic disease, Department of Health, Odedina (PI) and Segal (Co-PI), \$85,831.50, 2011-12.

“Florida Community Health Workers Effectiveness Project: evaluation of the effectiveness of CHWs,” Department of Health, Odedina (PI) and Segal (Co-PI), \$58,982.50, 2011.

11032107 “Florida Community Health Workers Project: Assessment of employers’ needs,” Department of Health, Odedina (PI) and Segal (Co-PI), Funded for \$30,000, 2011.

"Medicaid Meds-AD Program Phase II Medication Therapy Management Evaluation" (Lipowski PI, Segal Co-PI). Agency for Health Care Administration, approved for funding, awaiting funding level from Agency.

“Community Health Workers (CHW) Research and Training Institute,” Funded as a Cluster Award by the Florida Board of Governors for \$600,000, Dec 2010 – Dec 2011, (PI: Odedina and Tucker); Role: Co-Inv responsible for program evaluation.

“Evaluation of Medication Therapy Management (MTM),” Gold Standard (Segal PI and Angaran PI, July 2010 – June 2012, Funded for \$150,367.

The Science of Global Prostate Cancer Disparities in Black Men, (Segal, Co-Inv), NIH/NCI, 1R13CA144439-01 Funded for \$20,000, May 2010-May 2012.

"Increasing Community Pharmacists Smoking Cessation Counseling Rates through Professional Moral Engagement," Segal (PI) and Lee (Fellow), AFPE, Funded for \$6,000.

"Evaluation of Disease Management Programs in Hemophilia and HIV," Agency for Health Care Administration (Hartzema PI, Segal Co-PI), 2009-11, Funded for \$215,954.

"Evaluation of Medicaid Meds-AD Program," (Lipowski PI, Segal Co-PI). Agency for Health Care Administration, Funded for \$710,000, July 2008 - December 2010.

Fl. Dept of Veterans Administration. Evaluation of Stroke for N. FL/S. GA. VARMC Rehab. (Segal PI). 7/1/2007-6/30/2008. Funded for \$65,000.

Fl. Dept of Veterans Administration. Evaluation of Stroke for N. FL/S. GA. VARMC Rehab. (Segal PI). 7/1/2006-6/30/2007. Funded for \$63,946.

Formative Evaluation of an INR Home Monitoring Program in the VA Sunshine Healthcare Network. (Segal, Co-PI, Ried Co-PI). Funded for \$32,000, 2005-06.

Fl. Dept of Veterans Administration. Evaluation of Stroke for N. FL/S. GA. VARMC Rehab. (Segal PI). 7/1/2005-6/30/2006. Funded for \$63,000.

Pfizer; (Segal, PI), "Managed Care Pharmacoeconomics Post-Doctoral Fellowship." Funded for \$65,236, 2005-06.

Evaluation of Diabetes Extension in Florida Medicaid. (Segal, PI). Agency for Health Care Administration, Funded for \$119,914, 2004-05.

Fl. Dept of Veterans Administration. Professional Services for N. FL/S. GA. VARMC Rehab. (Segal PI, Kwon). 7/1/2005-6/30/2006. Funded for \$71,028.

Florida Center for Medicaid and the Uninsured/Agency for Health care Administration; (Segal, Co-PI 7.5%), "An evaluation of enhancements in electronic technology for prescribers in Florida Medicaid program, 8/03-06/04, Funded for \$20,000.

Florida Center for Medicaid and the Uninsured/Agency for Health care Administration; (Segal, Co-PI 7.5%), "Identification and treatment of Medicaid recipients with Hepatitis C," 8/03-12/03: Funded for \$20,000.

Agency for Health Care Administration; (Segal, Co-PI; 10%; Frank, PI), "Evaluation of Diabetes and Behavioral Health Interventions in Florida Medicaid;" 03/03-6/04: Funded for \$432,708 total.

Development of a screening tool for medication errors in hospital inpatients. Funded for \$50,000 by Research Opportunity Fund 2001 of the University of Florida Research and Graduate Programs, 5/01 - 4/02 (co-investigator).

Fellowship in Pharmacoeconomics and Health Outcomes. Funded for \$49,000 by Pfizer, 2001-02.

Clinical Pharmacy Demonstration Project in Community Health Centers. Funded for \$250,000 by the Bureau of Primary Health Care, HRSA, 2001-03 (role: co-investigator and research director).

University of Florida Research Foundation Fund. Funded for \$3,000, UFRF, 1999-2001.

Integrated Orlistat/Diet Intervention in Medicaid Type II Diabetes Enrollees. Funded for \$153,000 by Roche, 2000-02.

Outcomes Assessment of Low Molecular Weight Heparin in Columbia/HCA Hospitals. Funded by Pharmacia & Upjohn, \$110,000, 2000-01.

Fellowship in Pharmacoeconomics and Health Outcomes. Funded for \$45,000 by Pfizer, 2000-01.

Fellowship in Diabetes Health Outcomes. Funded for \$51,411.15, MedMatRx and Pfizer Health Solutions, 1999-2000.

HIV Health Management Initiative. Funded for \$215,000 Agency for Health Care Administration, 1999 – 2000.

CD-ROM Training for Distance-Based Learning. Funded for \$70,000 by Department of Health, 1998-99 (Karen Bentrup, PI, Florida AIDS Education, and Training Centers Network).

Evaluation of Phase I Data for the HIV Health Management Initiative, Funded for \$10,000 by the Health Council of South Florida and the Agency for Health Care Administration, 1998

Cost Analysis of Patients Hospitalized with Lower Respiratory Tract Infections and Abdominal Infections. Funded by Merck for \$100,000, 1998-99.

The Eckerd Cardiovascular Outcome Improvement Project. Funded for \$186,000 by Pfizer, 1998-99.

Identifying Barriers to Clinical Practice Guideline Utilization. Funded for \$14,511 by Hoechst Marion Roussel, 1997-98.

The Eckerd Respiratory Outcome Improvement Project. Funded for \$100,000 by Hoechst Marion Roussel, 1998.

Partnership in Implementing a Health Management System in a Managed Care Organization. Funded for \$446,392 by Astra Merck, 1996-98.

Improving the Implementation of a Health Management System. Funded for \$7,873.74 by Division of Sponsored Research, University of Florida, June 1996.

Economic and Social Costs of Osteoporosis for Patients in a Family Practice Medical Group. Funded for \$20,000 by Merck Inc. (Donna Berardo, principal investigator), 1996.

Pharmacoeconomic Decision Making. Funded for \$60,000 by Astra Merck, 1996 (Doug Hepler, principal investigator).

Evaluating Continuous Quality Improvement Tools Associated with Clinical Performance Indicators. Funded for \$25,000 by Astra Merck, 1995, and \$1,300 by Merck Human Health, 1995.

Managing Peptic Acid Disease; An Outcomes Analysis. Funded for \$3,000 through an educational grant from Astra/Merck, 1994.

An Assessment of Ethnic Differences in Drug Use Decision-Making among African American and White American Hypertensive Patients: Implications for Hypertension Management. Funded for a total of \$17,641 (\$4,050 by Marion Merrell Dow Inc.; \$2,000 by Bristol Myers Squibb, \$6,590.23 by Division of Sponsored Research, University of Florida; \$5,000 by Center for Rural Health and Aging, University of Florida) 1993-94.

Evaluation of the Cost-Effectiveness of Medical and Drug Treatments for Peptic Acid Diseases in University - Affiliated Family Practice Offices. Funded for \$15,000 by Astra/Merck Group, 1993.

Alternative Treatments for Patients with Initial Symptoms of Acid Peptic Disease: Cost and Quality Analysis. Funded for \$68,140 by Merck Human Health, 1993.

Costs and Preventability in Asthma: A Study of Emergency Department Visits and Subsequent Hospitalizations. Funded for \$31,122 by Glaxo, Inc, 1992.

Drug Usage Evaluation and Intervention in the AIDS Population. Funded for \$50,000 by NIH SBIR Phase I Program, 1992 (D. Robinson, P.I.).

Therapeutic Outcomes Monitoring in Community Pharmacy. Funded by Sandoz Pharmaceuticals for \$200,000; 1991-93, (Charles D. Hepler, P.I., R Segal, Co-P.I., D. Ried, CO-P.I.).

Improving the Quality of Drug Usage in a Cost-Effective Manner. Funded by Merck Sharp & Dohme Gastrointestinal Division for \$168,234; 1991-92. (D. Robinson, P.I.).

Parenteral Histamine-2 Receptor Antagonist Drug Use Evaluation and Cost Analysis. Funded by Merck, Sharp & Dohme for \$45,500, 1991.

Explaining Post-Purchase Outcomes in Prescription Drug Market: An Application of Equity Theory and Gap Analysis. Funded by Marion Merrell Dow, Inc. for \$35,000, 1990-91. (Dev S. Pathak, Ohio State University, Principal Investigator).

Examination of Drug Product Selection by Pharmacists Using Computerized Data Bases. Funded for \$5,277 by Division of Sponsored Research and the College of Pharmacy, University of Florida, 1989.

Medication Use and Cost Study for the East Central Florida Regional Planning Council. Funded for \$5000 by the University of Florida College of Pharmacy, 1989. (H. Eng, Principal investigator).

Relationship between Medication Compliance and Patient Outcome in Kidney Transplant Patients. Funded for \$5000 by the American Society of Hospital Pharmacists Research and Education Foundation, 1988-89.

Analysis of H₂ Blocker Prescribing in ICU's. Funded for \$500 by Smith Kline, and French, 1988.

Survey of Critical Care Pharmacy Practice. Funded for \$2500 by Baxter Healthcare Corporation, 1988. (J. Dasta, P.I.)

Quality Assurance for a Clinical Pharmacy Patient Education Program on Pain Management. Funded for \$5000 by the American Society of Hospital Pharmacists Research and Education Foundation, 1987-88.

Impact of Medication Counseling by Pharmacists in the Veterans Administration Setting. Funded for \$5000 by the American Society of Hospital Pharmacists Research and Education Foundation, 1987-88.

Mobile Pharmacy and the Elderly: A Feasibility and Evaluation Study. Funded for \$9000 by The Ohio State University Research Challenge Program, 1987. Funded for \$3200 by The Ohio State University Academic Challenge Program to purchase equipment, 1987.

An Evaluation of a Clinical Pharmacist on Family Practice Medical Resident's Antibiotic Prescribing. Funded for \$350 by the Central Ohio Society of Hospital Pharmacists Research Grant Program and recipient of COSHP Research Award, 1987.

Comparison of Ibuprofen, Placebo, and Fentanyl as Analgesic Components of General Anesthesia in Ambulatory Surgery. Funded for \$500 by Merck, 1987. (J. Visconti, P.I.)

The Impact of a Clinical Pharmacist on Family Practice Medical Residents' Antibiotic Prescribing: A Controlled Multi-Institutional study. Funded for \$4985 by the American Society of Hospital Pharmacists Research and Education Foundation, 1986-87.

Development of a DataBase to Assist in the Dispensing Fee Determination for Participating Pharmacy Providers in the Ohio Medicaid Program. Funded for \$9,980 by the Bureau of Medicaid Policy, Ohio Department of Human Services, 1986.

Identification of Factors Involved in Generic Substitution by Pharmacists. Funded by Smith, Kline Beckman, Inc. for \$4500, 1986-87.

Assessment of Methods to Detect Adverse Drug Reactions. Funded for \$3500 by the Roche Hospital Pharmacy Research Grant Program, 1986-87.

A Study of the Impact of a Flexitime Program on Work-Related Measures. Funded for \$350 by the Central Ohio Society of Hospital Pharmacists and recipient of COSHP Research Award, 1985.

Marketing Audit of Community Pharmacies. Funded for \$2500 by Scott Krauss Inc., 1985.

A National Audit of Antineoplastic Admixture Practice. Funded for \$2500 by the Roche Hospital Pharmacy Research Grant Program, 1985-86.

Salary and Fringe Benefit Survey for Ohio Pharmacists. Funded for \$800 by The Ohio State Pharmaceutical Association and The Ohio Society of Hospital Pharmacists, 1984.

An Evaluation of Advertising Strategies for Independent Community Pharmacies. Funded as a Grant-in-Aid for \$1000 by the Norcliff-Thayer-NARD Program, 1984.

Predicting Physician Compliance with Drug Therapy Recommendations in Skilled Nursing Facilities. Funded for \$2000 by the Larry Niemerow Foundation of The American Society of Consultant Pharmacists, 1983-84.

Predicting the Formulary Decision-Making of Pharmacy and Therapeutic Committee Members. Funded for \$3449 by the American Society of Hospital Pharmacists Research and Education Foundation, 1983-84.

A Study of a Cognitive Model of Drug Prescribing. Funded for \$4500 by the American Society of Hospital Pharmacists Research and Education Foundation, 1982-83.

A Study of a Cognitive Model of Physician Data Collection. Funded for \$1750 by the A.D. Williams Foundation, 1982.